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ABSTRACT
IKAROS is expressed throughout the entire hematopoietic system and is required
for lymphoid commitment and subsequent differentiation towards the B-lymphoid fate.
If absent, progenitor and mature B-cell subsets are not expressed. IKAROS (encoded by
IKZF1) is a zinc-finger transcription factor shown to regulate gene expression either
directly or through the recruitment of chromatin remodeling complexes. The epigenetic
gene regulatory mechanisms, including the posttranslational modification to histone
proteins, as well as the expression of noncoding RNAs (ncRNAs) are important to control
as perturbations in these processes contribute to the manifestation of human diseases. If
left unregulated, uncontrolled growth, aberrant cell activation, and altered signaling
cascades can arise. In this dissertation, I utilize functional genomic approaches to
characterize the genome-wide chromatin and epigenetic patterns regulated by IKAROS
in the context of two B-cell-related disorders.
In the first part of this dissertation, patient-derived xenograft cell models were
used to study the tumor-suppressor mechanism of IKAROS. The dominant negative-IK6
isoform is highly expressed in a B-cell lineage subtype of acute lymphoblastic leukemia
(ALL) with an especially poor prognosis called precursor-B ALL (pre-B ALL). To
restore wildtype IKAROS expression (IK1) in human pre-B ALL cells that expressed the
IK6 isoform, we used a doxycycline inducible (DOX) expression system. We then set
out to study the global transcriptional patterns of DN-IK6 pre-B ALL cells in response
to IK1-induction. Overall, our results show that one potential mechanism in which
IKAROS regulates growth suppression in pre-B ALL is by regulating the expression of
ncRNAs.
In the second part of this dissertation, I investigate the role of Ikaros in regulating
an epigenetic program required for the proper activation of naïve B-cells. Ikaros and other
Ikaros family members have been linked to autoimmune diseases, but the molecular
mechanisms have yet to be described. Here, I characterize the global chromatin and
transcriptional landscape of B-cells isolated from mice containing a targeted deletion in
the Ikzf1 zinc finger domain (Ikzf1DF4/DF4). This murine model contains mature B-cells
which require only the first signal to become activated and proliferate, thus having a
hyper-reactive response and break in central tolerance. Taken together, we offer two
separate epigenetic mechanisms by which Ikaros regulates gene-expression programs
ultimately leading to a break in B-cell tolerance. The first is through the regulation of
active enhancers, and the second is through a developmental mechanism of silencing via
regulation of H3K27me3 and H3K4me3 signal.
In total, this dissertation provides further insight into the epigenetic and chromatin
regulation of B-cells at two separate stages of development and provides insight into the
mechanisms underlying the Ikaros tumor suppressor function and its role to maintain an
epigenetic landscape required for proper B-cell activation.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW
1. Overview of B-cell development and transcription factor expression during B
lymphopoiesis
1.1 B-cell development
All blood cells are derived from hematopoietic stem cells (HSCs) in the bone
marrow through a multi-step process called hematopoiesis (Figure 1-1). HSCs differentiate
into restricted multipotent progenitors (MPPs) which branch into either the early progenitor
of the myeloid and lymphoid lineage called the common myeloid progenitor (CMP) and
the common lymphoid progenitor (CLP). Numerous cell types are derived from the CMP
precursor including macrophages, erythrocytes, megakaryocytes, and granulocytes [1].
While other cell types, such as NK-, T-, and B-cells, are derived from the CLP [2].
In an effort to distinguish functional CLPs from other B-cell progenitors and better
characterize the T- and B- branchpoint, Inlay and colleagues developed the computation
method Mining Developmentally Regulated Genes (MiDReG) [3]. This analysis identified
26 genes that were differentially expressed (DE) during murine B-cell development, and
identified Ly6d as the cell surface marker capable of distinguishing two distinct subsets
within the CLP stage [3]. The Ly6d- subset was termed the all-lymphoid progenitor (ALP)
and the Ly6d+ subset was termed the B-cell biased lymphoid progenitor (BLP) as all Bcell precursors are derived from BLP [3]. These include the pro-B, pre-BI, large and small
pre-B II, and immature B-cell subsets [4, 5]. The pro-B cells are generally defined by the
presence of CD19+. In the next stage, pre-B cells express the pre-B cell receptor (pre-BCR)
which serves as an important checkpoint of functional B-cell receptor (BCR) allowing for
subsequent differentiation into the next stage. The cell surface marker CD34 is highly
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expressed in HSCs and is subsequently used for HSC isolations, however, by the pre-B
stage CD34 is shown to be significantly downregulated [6]. During the final stage of
development, immature B-cells exit the bone marrow and migrate to the secondary
lymphoid organs.

Figure 1-1 Overview of hematopoiesis. Highlight in B-cell development. Commitment into the
lymphoid lineage begins from HSC differentiation into MPP and into the CLP stage. The myeloid
precursors are derived from CMP. The stages of B-cell development in the bone marrow and spleen
are shown. Adapted from Boller and Grosschedl, 2014.

1.2 B-cell lineage transcriptional program
1.2.1 Lineage specific TFs are required for B-cell commitment
In addition to external stimulus such as cytokines, internal factors like the
expression of specific transcription factors (TFs) are required to promote and facilitate cellfate decisions [7-9]. Commitment into the lymphoid lineage is modulated by the
2

coordinated action of multiple TFs that initiate lineage priming to ensure the activation of
the lymphoid program and silencing of alternative cell fates [10, 11]. Over the past few
decades, studies have identified several key regulators of early B-cell development which
include factors such as EBF, PAX5, PU.1, and Ikaros (Figure 1-2) [12, 13]. Together,
these TFs sustain the expression of lymphoid-specific genes and repression of genes
required for myeloid lineage potential.
For example, PU.1 is an ETS family transcription factor required for the
development of many hematopoietic lineages as germline deletions of the Sfpi1 (gene
encoding PU.1) results in severe defects to both myeloid and lymphoid differentiation [5,
14]. It has been shown that the concentration of PU.1 determines if B-cells versus
macrophages develop, where high expression of PU.1 favors macrophage differentiation
[15]. Ikaros, a hemopoietic-specific zinc finger transcription factor, was shown to support
Gfi1 expression which attenuates PU.1 expression in MPPs, thus promoting the generation
of lymphocytes in lieu of myeloid progeny [16].

Figure 1-2: TF coordination required for B-cell lineage commitment. Key transcription factors
involved in the B-cell lineage commitment are shown. Positive interactions are shown with an arrow.
Negative interactions are indicated by repressive mark. Adapted from Salerno et al., 2015.

3

1.2.2 Ikaros is required for B-cell development
There are many well-known examples of targeted deletions of transcription
factors required for the lymphoid lineage which result in disruptions to B-cell
differentiation [17, 18]. Here, murine models which describe the essential role for Ikaros
(encoded by Ikzf1) in normal B-cell development will be discussed. Georgopoulos et al.
was the first to describe a murine model which harbored an 8.5 kb targeted deletion within
the Ikzf1 DNA binding domain (Ikzf1DN/DN), specifically targeting zinc fingers 1-3 (ZnF1ZnF3) [13]. This resulted in a dramatic difference in size when comparing pups from
Ikzf1WT/WT and Ikzf1DN/DN at 1-4 weeks of age [13]. Importantly, this study established that
Ikzf1DN/DN mice also lacked mature T- and B-cells indicated by the absence of CD4+/CD8+
or CD3+/TCR and CD45R+/IGM+ cells in the spleen, respectively [13]. In late 1996, the
most comparable mutation that resulted in a total loss of mature T- and B- cell was the
RAG1-deficient murine model [19].
Later, the same group characterized another Ikaros murine model which harbored
a targeted deletion at the C-terminus of the Ikzf1 gene (Ikzf1null/null) [20]. The Ikzf1null/null
model resulted in a complete abolishment of both fetal and adult B-cells indicated by the
absence of the B220 [20]. However, thymocytes were detected in the Ikzf1null/null thymus
although drastically reduced in numbers [20]. Interestingly, when thymocytes or spleen
cells from Ikzf1null/null were stimulated with anti-TCR, they found that these cells
proliferated more than thymocytes harvested from wild-type (wt) mice after performing
[3H] thymidine incorporation experiments [19]. Yet, these studies were unable to study the
role of Ikaros in mature B-cells as these cells were absent in the models discussed.

4

Next, Schjerven and colleagues set out to understand if targeted disruption to
select ZnF resulted in changes to Ikaros target genes [21]. Germline deletion of exon 4 or
exon 6 in embryonic stem cells were performed to generate Ikzf1ΔF1/ΔF1 (ZnF1) or
Ikzf1ΔF4/ΔF4 (ZnF4) respectively [21]. This deletion generated an Ikaros mutant protein
lacking a zinc finger [21]. In contrast to the Ikzf1DN/DN and Ikzf1null/null, both the Ikzf1ΔF1/ΔF1
and Ikzf1ΔF4/ΔF4 models resulted in the presence of CD19+B220+ cells in the femurs and
spleen, although reduced in numbers [21]. A key difference between the Ikzf1ΔF1/ΔF1 and
Ikzf1ΔF4/ΔF4 mice, are that the Ikzf1ΔF4/ΔF4 developed thymic lymphoma by 12 weeks of age
while Ikzf1ΔF1/ΔF1 mice did not [21]. A complete summary of the Ikzf1-mutant murine
models discussed is summarized below (Table 1-1).

Table 1-1: Summary of the Ikzf1-mutant murine models
Mutation

Ikzf1DN/DN

Ikzf1null/null

Target

Phenotype

Reference

Exon 4-5,
ZnF1-3

Smaller pup size at 1-4 weeks
Lack of mature T, B, NK-cells
Lack of inguinal, cervical, axillary, and
mesenteric lymph nodes
Lack mature thymus
Enlarged spleen (splenomegaly)
95% of mice died in first four weeks
Develop thymic lymphoma at four months

[13]

Lack of fetal and mature B- cells
100-300X fewer thymocytes at 3-6 days
Reduction of CD4+, CD8+ T cells in
spleen at 3 weeks
Lack of inguinal, cervical, axillary,
mesenteric lymph nodes, Peyer’s patches,
and lymphoid follicles
Lack of NK cells

[20]

Exon 8,
ZnF5-6

5

Mutation

Target

Phenotype

Reference

Ikzf1ΔF1/ΔF1

Exon 4,
ZnF1

Reduction of CD19+B220+ cells in spleen
at 6 weeks old
Reduction in small pre-BII cells in BM

[21]

Ikzf1ΔF4/ΔF4

Exon 6,
ZnF4

Reduction of CD19+B220+ cells in spleen
at 6 weeks old
Reduction in small pre-BII cells in BM
Reduction in CD4+/CD8+ thymocytes
Absence of inguinal and lumbar lymph
nodes
Development of spontaneous thymic
lymphoma by 12 weeks of age

[21]

1.3: Ikaros protein structure and function
Ikaros was first described in the early 1990’s as a transcriptional regulator,
approximately 50-kDa, and containing two separate C2H2 domains: one located near the
amino (N) terminus and another at the carboxy (C) terminal end [22, 23]. The N-terminal
domain contains four ZnFs (ZnF1- ZnF4) each within exon 4-6 that bind DNA through the
consensus sequence PyPyTGGGAGPu. The C-terminal domain contains two ZnFs (ZnF5ZnF6) within exon 8 that are required for protein-protein dimerization [23, 24] (Figure 13). Shortly after, it was reported that IKZF1 was alternatively spliced generating Ikaros
proteins with different combinations lacking regions encoding exons 3-6 (described as IK1IK6) [25, 26]. Biochemical studies performed demonstrated that ZnF2 and ZnF3 are
required for binding to DNA, while flanking ZnF1 and ZnF4 modulate binding to certain
DNA sequences [21, 25]. For example, it was shown that IK1 (containing ZnF1-ZnF4) was
capable of binding 8 out of the 9 oligonucleotides incubated with regardless of the
6

variations of the recognition sequence, while IK3 (containing ZnF1-3) was only capable of
binding 4 out of the 9 oligonucleotides [25].
The IK1 and IK2 isoforms are the most highly expressed in the thymus and spleen
whereas IK3-IK5 are lowly expressed at these sites [25]. To increase their affinity to DNA,
the IK1-IK3 isoforms are known to homo- or heterodimerize to activate gene transcription
[24]. Dimerization of IK1 with IK6 causes a reduction in the ability of Ikaros to bind DNA,
thus IK6 exerts a dominant-negative (DN) effect [24]. Deregulated expression of the DNIK6 isoform has been shown to be highly expressed in a B-cell lineage subtype of acute
lymphoblastic leukemia (ALL) with an especially poor prognosis called precursor-B ALL
(pre-B ALL) [27]. This will be discussed more in a separate section.
There are four other Ikaros family members which include: Helios, Aiolos, Eos,
and Pegasus (encoded by IKZF2-IKZF5). All isoforms have four N-terminal ZnFs
comprising the DNA-binding domain, with the exception of Pegasus. Ikaros is able to bind
and regulate the transcription of DNA by homo-dimerizing or hetero-dimerizing with other
family members. Like Ikaros, Aiolos, and Helios are also expressed throughout
lymphocyte development [28, 29]. In contrast, Eos and Pegasus are not expressed in Bcells but are expressed in the liver, skeletal muscle, kidney, and heart tissues [30].
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Figure 1-3: Ikaros isoforms and family members. Adapted from Marke et al., 2018.

1.4: Alterations in Ikaros are linked to human disease
1.4.1 B-cell Acute Lymphoblastic Leukemia
Leukemia is a cancer of developing blood cells that can occur at any age, and is
the most common cancer in children, accounting for nearly one-third of all pediatric
cancers [31]. The most common type of pediatric leukemia is acute lymphoblastic leukemia
(ALL). ALL is characterized by the rapid growth of abnormally developing lymphoid cells
within the bone marrow, which restricts the production of normal blood cells. As a result
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of improvements in the treatment of ALL, including the development of targeted therapies,
the five-year survival rate for children with standard risk ALL is 93% [32-34]. However,
relapsed ALL remains a major cause of cancer-related death and the prognosis for ALL
declines drastically with age, where the five-year survival rates in adults 40 years and older
remains just over 30% [35].
Acute lymphoblastic leukemia is classified by cell lineage. The two main forms
of ALL are B lymphoblastic and T lymphoblastic ALL [36]. B lymphoblastic ALL (BALL) is the most common form of pediatric cancer, accounting for nearly 80% of pediatric
ALL [37]. B-ALL can be further classified according to recurrent driver genomic lesions
including chromosomal aneuploidy, rearrangements that result in fusions that deregulate
proto-oncogenes or transcription factors, and point mutations [34]. Accordingly,
cytogenetic and molecular analysis is important for the clinical management of B-ALL,
providing a basis for risk stratification, and in some cases treatment with targeted therapies
[38]. For example, among the aneuploidy groups, one subset is termed high hyperdiploidy
(HdH; containing 51–65 chromosomes) and is found in one-third of children with ALL
[39]. Similarly, the reciprocal translocation t(12;21)(p13;q22) generating the fusion gene
ETV6/RUNX1 (also known as TEL/AML1) is also common, accounting for nearly 25% of
pediatric B-ALL cases [38]. Clinically, the prognosis is favorable for both HdH and
ETV6/RUNX1 subtypes with five-year overall survival rates near 80% [39, 40]. In contrast,
in high-risk subtypes such as BCR-ABL1-positive (also known as Philadelphia
chromosome-positive, Ph+) B-ALL the incidence increases with age and is associated with
poorer prognosis [38]. Specifically, patients with Ph+ make up approximately 5% of BALL cases in children and account for 40-50% of B-ALL cases in adults [35]. Outcomes
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for Ph+ B-ALL have improved with the administration of imatinib, a tyrosine kinase
inhibitor (TKI), however resistance to these treatments can occur [41, 42]. Despite the
utility of prognostic biomarkers, unanswered questions remain regarding the relationship
of genomic alterations to leukemogenesis, chemotherapy resistance, and clinical outcome.
As new molecular signatures of B-ALL emerge, the possibility of improved
prognostication and treatment stratification may reduce treatment failure and relapse
associated with B-ALL.
1.4.1.1 IKAROS and B-cell Acute Lymphoblastic Leukemia
Alterations in IKZF1 are present in approximately 15% of pediatric B-ALL cases
and 40% of adult patients with B-ALL [43]. The prevalence of somatic mutations in IKZF1
dramatically increase when considering the high-risk subtype Ph+ B-ALL (Ph+ pre-B
ALL) [44]. Here, upwards of 80% of Ph+ B-ALL patients have deletions in IKZF1 most
commonly involving deletions of exons 3-6 encoding an IKAROS protein that lacks the
DNA-binding domain (IK6) [44]. The mechanism by which the IK6 isoform arises is
through aberrant RAG-mediated recombination [44]. Unfortunately, the presence of the
IK6 isoform in Ph+ pre-B ALL is associated with poorer survival and increased risk of
relapse compared to Ph+ pre-B ALL patients with IK1 [45].
Thus, an increased understanding of the molecular mechanisms by which IKAROS
suppresses leukemogenesis will aid in understanding the leukemia tumor suppressive
programs and may direct the development of novel therapeutics that target IKZF1-mutated
leukemia. Of interest is emerging evidence that indicates various non-coding RNAs
(ncRNAs) expression patterns are associated with disease subtype and can be used as
prognostic markers for pre-B ALL.
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1.4.1.2 Noncoding RNAs are clinically significant in B-cell Acute Lymphoblastic
Leukemia
Global gene expression profiling has provided considerable new insight into the
molecular basis of B-ALL, including the identification of distinct high-risk subgroups [46,
47]. Moreover, transcriptome-wide profiling by RNA-Seq has identified non-coding RNAs
(ncRNAs) as central players in cancer progression [48]. Diverse classes of ncRNAs
including small and long non-coding RNAs (lncRNAs) have been defined as key
regulatory factors that may have significant roles in determining cancer phenotypes [49].
A growing number of studies indicate that these two major types of ncRNAs may play
critical roles in the pathogenesis and progression of B-ALL and may serve as prognostic
biomarkers or provide opportunities as new therapeutic targets.
1.4.1.3 A Compendium of Human Non-Coding RNA Genes
A remarkable number of genes in the human genome are transcribed into proteincoding and various non-coding RNA species (Figure 1-4). Comprehensive and current
gene annotations provided by the GENCODE [50] and RefSeq projects [51] are
indispensable resources for the investigation of the coding and non-coding RNA landscape
of the human genome [52], where non-coding genes represent nearly half of all annotated
genes.
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rRNA
tRNA
scaRNA
rRNA_psuedogene
protein-coding
33%
pseudogenes
24%

small
non-coding
13%

long non-coding
30%

snoRNA

943

miRNA

1881

snRNA

1901

misc_RNA 2212

Figure 1-4 Diagram showing the major classes of genes contained within the human genome based on
GENCODE annotation version 36 (https://www.gencodegenes.org/human/). The small RNA genes
are composed of a variety of different biotype annotations. Shown in the stacked barplot are the
small non-coding gene types, along with numbers of genes per category from the HGNC project
(https://www.genenames.org/download/statistics-and-files/). (Abbreviations: rRNA, ribosomal RNA;
tRNA, transfer RNA; scaRNA, Small Cajal body-specific RNA; snoRNA, small nucleolar RNA;
miRNA, microRNA; snRNA, small nuclear RNA; misc_RNA, miscellaneous RNA).

The non-coding genes can be grouped into two broad categories according to the
nucleotide (nt) length of the RNA transcripts: long non-coding RNA (lncRNA; > 200 nt)
and small non-coding RNA (< 200 nt). The number of non-coding RNA genes annotated
in the current GENCODE annotation (version 36) includes 17,958 lncRNA genes and over
7,569 small RNA genes, comprising approximately 30% and 13% of all the annotated
human genes in this reference. Due to the continual emergence of new data, as well as the
improvements and increased application of long-read sequencing technologies, these gene
annotation resources are continually updated, providing a more complete annotation of
ncRNA genes [53]. Additionally, many resources exist to curate and systematically classify
ncRNAs including the HUGO, NONCODE and LNCipedia databases [54-56].
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1.4.1.4 miRNAs Are Regulatory Small Non-Coding RNAs
In general, ncRNAs have been shown to function in numerous physiological and
developmental processes. The small RNA genes are comprised of several different
biotypes including microRNA, snRNA, snoRNA, rRNA, tRNA, vaultRNA and Y-RNA.
Many of these small ncRNAs with abundant and ubiquitous expression across cells
participate in general housekeeping functions, including mRNA splicing and translation
(i.e., rRNAs, tRNAs, snoRNAs, etc.). Additionally, some small RNAs (i.e., miRNAs, YRNAs, etc.) can be released from the cell and are detectable in biofluids such as plasma,
serum, and bronchoalveolar lavage fluid [57].
Studies have found that many small ncRNAs are considered dynamic regulatory
RNA molecules with functional roles in post-transcriptional gene regulation. In particular,
microRNAs (miRNAs) are well known to play central regulatory roles through post‐
transcriptional gene regulation via direct binding to mRNAs (reviewed in [58]). It is
predicted that the majority (> 60%) of mRNAs can be bound by miRNAs [59] and
accordingly, miRNAs have been widely connected to diverse human diseases, including
cancer and B-ALL, as reviewed below [60]. MiRNA genes are transcribed as long primary
transcripts (pri-miRNAs) and are sequentially processed into precursor miRNAs (premiRNAs) and then into mature miRNAs, approximately 22 nucleotides in length. As
ribonucleoprotein complexes mature, miRNAs bind specific mRNAs that are
complementary to the miRNA sequence, which results in target mRNA degradation or
translational repression (for a review, see [61]). The miRNA:mRNA interaction is subject
to various regulatory steps, including the subcellular location of miRNAs, the expression
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levels of miRNAs and various target mRNAs, as well as the expression of other RNA
transcripts that alter miRNA function.
1.4.1.5 Regulatory Long Non-Coding RNA (lncRNA)
Similar to protein‐coding mRNAs, many lncRNA genes are transcribed by RNA
polymerase II, then capped, spliced and polyadenylated [62]. As a group, lncRNA genes
are generally poorly conserved across mammals and exhibit low expression levels and/or
cell or tissue-specific expression patterns [63]. In an effort to classify lncRNAs, lncRNA
genes are grouped based on their position relative to protein-coding genes, including: i)
intergenic lncRNA, ii) antisense lncRNA, iii) divergent lncRNA (bidirectional promoter),
iv) intronic lncRNA, and v) overlapping lncRNA [64]. In comparison to miRNAs, whose
functions have been extensively characterized, much less is understood about lncRNA
genes as functional studies have only been performed for a limited number of lncRNAs
[54].
Despite there being only a small fraction of lncRNA genes described in the
literature, current evidence indicates that lncRNAs play diverse biological roles.
Depending on their specific interactions with DNA, RNA and proteins, lncRNAs have been
reported to modulate chromatin structure, control the assembly and function of various
nuclear complexes, regulate the translation of mRNAs, and restrict various cellular
signaling pathways (reviewed in [65]). The different modes of lncRNA action can be
grouped into five broad categories, as follows. First, lncRNAs contribute in the cisregulation of neighboring genes. This can occur through chromatin modulation whereby
lncRNAs interact with DNA to form RNA-DNA hybrids such as R-loops that recruit
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transcription factors [66] or chromatin modifiers [67-69] to modulate gene transcription or
to directly induce transcription [70].
Second, lncRNAs participate in the trans-regulation of a gene locus (or many loci)
distal from the lncRNA gene through similar mechanisms involving chromatin
modification [71, 72]. Third, lncRNAs act as structural modules that mediate protein and
RNA complexes (ribonucleoproteins or RNPs). LncRNA-containing RNP complexes have
been implicated in a wide variety of cellular processes ranging from transcription, premRNA processing, chromatin modification, and cellular signaling (reviewed in [73]).
Fourth, lncRNAs can function as molecular “decoys” or “mimics” to sequester proteins or
small RNAs from their targets. For example, an abundant lncRNA called NORAD (for
"noncoding RNA activated by DNA damage") binds to the RNA binding proteins PUM1
and PUM2 to insulate them from the mRNAs to which they bind, which include genes
involved in chromosome segregation during cell division [74, 75]. Finally, numerous
lncRNAs have been described as “sponges” that sequester miRNAs from their target
mRNAs. The lncRNAs which function in this manner are commonly referred to as
competing endogenous RNAs (ceRNAs). These sponges or ceRNAs harbor a range of
miRNA response elements (MREs) that are complimentary to miRNAs. These lncRNAmiRNA interactions have been described (e.g., [76-78]).
1.4.1.6 Long Non-Coding RNAs in Progenitor B-cell Acute Lymphoblastic Leukemia
Several large-scale transcriptomic studies have described global gene expression
patterns of normal and malignant human hematopoietic cells (e.g., reviewed in [79, 80]).
The RNA landscape of the normal human hematopoietic hierarchy generated by RNA-Seq
and smRNA-Seq profiling methods from purified HSCs and their various differentiated
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progenies is now available [81]. Resources such as BloodSpot, Haemosphere, and other
publicly available databases contain valuable datasets for exploring the transcriptional
networks that underlie specific blood lineages and their associated hematological
malignancies [82-84]. For example, hundreds of lncRNAs exhibit cell-type/stage-specific
expression patterns across B-cell development and maturation in humans and mice,
whereby distinctive subsets of progenitor B-cells can be distinguished by lncRNA
expression patterns [85-89]. By mapping patient samples onto this landscape and other
normal expression profiles, signatures of upregulated lncRNAs in patient samples as well
as subtype-specific lncRNAs in B-ALL are emerging. Although the number of profiling
studies is limited, they clearly indicate that lncRNA expression patterns are deregulated in
B-ALL [90-92]. An assembled list of lncRNAs reported in B-ALL is provided in Table 12. The candidate lncRNAs identified in these studies provide a strong basis for further
studies aiming to identify their function or assess their potential clinical value.

Table 1-2: Examples of lncRNAs with significance in B-cell acute lymphoblastic leukemia.
LncRNA

neighboring
genes

B-ALL subtype
expression

BALR-1

C14orf132

BALR-2/
CDK6-AS1

CDK6

upregulated in
ETV6-RUNX1 and
High hyperdiploid
subtypes
ETV6-RUNX1,
TCF3-PBX1 and
MLL-rearranged
subtypes

BALR-6

SATB1, TBC1D5

highest
expression in
MLL-rearranged
subtypes

16

Clinical or
functional
implications
Unknown

References

High expression
correlated with
poor overall
survival and
reduced response
to prednisone
treatment
Promotes cell
survival in vitro

[91, 93]

[91, 93]

[91, 94]

LINC00958

TEAD1, RASSF10

TCL6

TCL1B

upregulated in
ETV6-RUNX1
ETV6-RUNX1

AL133346.1

CCN2

unknown

LINC00152/
CYTOR

intergenic; resides
in a cluster of
lncRNAs on
2p11.2
intergenic; resides
in a cluster of
lncRNAs on
6q23.2
LAMP5

unknown

CASC15/
LINC00340

SOX4

ETV6-RUNX1

DBH-AS1

DBH

unknown

lnc-NKX2-3-1

NKX2-3

lnc-TIMM21-5

NETO1

lnc-ASTN1-1

ASTN1

lnc-RTN4R-1

RTN4R,
CCDC188
TSPAN14,
SH2D4B

upregulated in
ETV6-RUNX1
upregulated in
ETV6-RUNX1
upregulated in
ETV6-RUNX1
upregulated in
ETV6-RUNX1
upregulated in BALL compared to
control pre-Bcells isolated from
human cord blood
High
hyperdiploid
and TCF3-PBX1

LINC01013

LAMP5-AS1

RP11-137H2.4/
lnc-DYDC1-1

GAS5

miRNA sponge

[91, 93, 95-97]

Low expression
associated with
poor disease-free
survival
High
AL133346.1/CCN2
expression
associated with
greater disease-free
survival
High expression
associated with risk
of early relapse

[98]

unknown

Low expression
associated with risk
of early relapse

[99]

MLL-rearranged

High expression
associated with
reduced diseasefree survival
Regulates
expression of
SOX4
Promotes cell
survival through
activation of
MAPK signaling
Unknown

[90, 100]

Unknown

[102]

Unknown

[102]

Unknown

[102]

Associated with
cell survival and
glucocorticoid
resistance in vitro

[93, 103]

Associated with
glucocorticoid
treatment
sensitivity

[104, 105]
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[93]

[99]

[91, 101]
[102]

[102]

1.4.1.7 MicroRNA and Progenitor B-Cell Acute Lymphoblastic Leukemia
MiRNAs play key biological roles during B-cell development and their
expression patterns are carefully regulated across distinct developmental stages [106, 107].
As we continue to discover and study miRNAs, those previously found to have important
roles in lymphopoiesis may also contribute to B-cell malignancies. There are currently
1,917 miRNAs registered in the Homo sapiens miRNA registry (miRBase version 22)
[108]. Of these, the LeukmiR database predicts 861 miRNAs are associated with ALL
[109]. One example is miR-150, which is a critical regulator of B-cell development and is
primarily expressed in the lymph nodes and spleen [110]. In B-cells, miR-150 expression
progressively increases during development where it is expressed at low levels in
progenitor cells and then becomes abundantly expressed in immature and mature B-cell
subsets [110]. Interestingly, ectopic expression of miR-150 has been shown to inhibit the
pro-B to pre-B transition and can modulate B-cell receptor signaling [111, 112]. In B-ALL,
microarray analysis has shown that miR-150 is lowly expressed in pediatric patients
compared to healthy controls [113]. Further, this study found that miR-150 expression
changed among prednisone response groups and was down-regulated in relapsed patients
compared to controls. In an effort to understand the role of miRNAs in B-ALL, several
groups have performed gene-expression studies in leukemic samples with the goal of
identifying miRNAs that could be used as diagnostic and prognostic markers, as well as
markers of resistance to existing therapies [114, 115]. An assembled list of miRNAs
reported in B-ALL is provided and discussed below (Table 1-3).
Table 1-3: Examples of microRNAs with significance in B-cell acute lymphoblastic leukemia.
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MiRNA

miR-125b

B-ALL
expression

Cohort description

Upregulated in
TEL-AML1positive
compared to nonTEL-AML1
precursor B-ALL

Mononuclear cells were isolated from
BM and PB from 81 ALL patients, of
which 70 were of the B-ALL subtype
and 11 were T-ALL. 17 control
samples were also included [116]

Upregulated in
patients
with
t(11;14)(q24;q32)
compared to BALL patients
without t(11;14)

Total RNA was extracted from
samples taken from 2 patients with
t(11;14)(q24;q32) translocations and
28 B-ALL patients without t(11;14)
for qPCR [118]

Upregulated in BALL
compared to TALL patients

Mononuclear cells were isolated from
BM and PB from patients diagnosed
with ETV6-RUNX1, TCF3 (E2A)rearrangement, MLL-rearrangement or
BCR-ABL1. Validation experiments
was performed on Reh cells [117]
See above [116]

Clinical or
functional
implications
Highly expressed
(along
with miR-100and
miR-99a)
in patients resistant
to vincristine [116,
117]

Refer
ences

When co-expressed
with BCR-ABL,
was shown to
accelerate the
development
of leukemia in
mice [119]

Unknown

[116]
,[120]
[121]

Higher expression
correlated with
chemotherapy
resistance [116]

[116],
[121]
[122],
[113]

BM or PB was obtained from 8
patients with ALL. Of these, 4 patients
had T‐ALL and 4 had B‐ALL [120]
miR-4255p

miR-126

Upregulated in
TEL-AML1positive
compared to nonTEL-AML1
precursor B-ALL

BM or PB was obtained from 20
patients with ALL and analyzed by
miRNA array. Of these, 4 had T‐ALL
and 16 had B‐ALL. In the B-ALL
cohort, 4 patients had a BCR/ABL
rearrangement, 3 had an E2A/PBX1, 3
had an MLL/AF4 rearrangement, and 6
patients had no molecular
abnormalities [121]
See above [116, 121]
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Higher
expression in
BCR/ABLcohort
compared to TALL patients

BM aspirates were collected from 17
B-ALL samples; 16 samples were
further studied. 11 were of the Ph+ BALL subtype and 5 were of the BALL ‘other’ subtype [122]

In xenotransplant
murine model,
knockdown
induced apoptosis
of B-ALL blast
cells [122]

Upregulated in BALL
compared
to healthy
controls
BM samples from 43 patients were
analyzed by microarray. These
included 18 ALL, 18 AML, and 7
normal samples. Among the ALL
samples, 17 were of the B-cell lineage
[113]
miR-34a

miR-130b

miR-146a

miR-213

miR-210

miR-128a

Upregulated in BALL compared
to healthy
controls
Upregulated in BALL compared
to healthy
controls
Upregulated in BALL compared
to healthy
controls
Upregulated in BALL compared
to healthy
controls

See above [113]

Unknown

[113]

See above [113]

Unknown

[113]

See above [113]

Unknown

[113]

See above [113]

[113]

Upregulated in BALL compared
to healthy
controls

See above [113]

Upregulated in BALL compared
to AML samples
and when
compared to
healthy controls.

See above [113]

Highly expressed
in high-risk and
intermediate risk
groups; not
abnormally
expressed in
standard-risk
group.
Highly expressed
in high-risk and
intermediate risk
groups; not
abnormally
expressed in
standard-risk
group.
Highly expressed
in ALL; can be
used in miRNA
expression
signature to
discriminate ALL
from AML
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[113]

[113],
[123]

BM samples were collected from 58
patients for miRNA expression
analysis. Of these, 11 were B-ALL
and 47 were AML. All B-ALL
samples had MLL-rearrangements. 14
cell lines were also included (7 ALL
and 7 AML). In addition, 3 BM
samples were collected from healthy
controls [123]
miR-128b

Upregulated in BALL compared
to AML samples
and when
compared to
healthy controls.

See above [113, 123]

miR-708

Upregulated at
relapse
compared to
complete
remission in
matched-paired
ALL samples

Matched-paired samples were
collected from 18 ALL patients at
diagnosis and at relapse or complete
remission for microarray studies. Of
these, 11 patients had B-ALL. 5
healthy control samples were also
included [124]

miR-1290

Upregulated in
ALL patients
with adverse
clinical
parameters
compared to
those with good
clinical
parameters
Downregulated in
ALL patients
with adverse
clinical
parameters
compared to
those with good
clinical
parameters
Downregulated in
ALL patients
with adverse
clinical
parameters
compared to
those with good
clinical
parameters

miR-1515p

miR-451

Highly expressed
in ALL; can be
used in miRNA
expression
signature to
discriminate ALL
from AML
Higher expression
correlated with
higher relapse free
survival in newly
diagnosed ALL
patients

[113],
[123]

BM samples from 48 patients were
analyzed by microarray of which 35
were of the B-cell lineage and 13 were
of the T-cell lineage. 32 of the B-ALL
samples from the initial cohort, in
addition to, 106 added B-ALL
samples (n=132) were used for
confirmation studies [125]

High expression
was associated
with increased risk
of relapse

[125]

See above [125]

Low expression
was associated
with increased risk
of relapse

[125]

See above [125]

Low expression
was associated
with increased risk
of relapse

[125]
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[124]

miR-150

Downregulated in
relapsed B-ALL
patients
compared to
complete
remission

See above [113]

Downregulated in
MLL-rearranged
compared to
compared to
MLL-negative
patients

See above[116, 123]

Let-7b

Downregulated in
B-ALL
compared to
AML samples

Downregulated in
B-ALL compared
to AML samples

See above [123, 124]

miR-223

miR-27a

Downregulated at
relapse compared
to complete
remission in
matched-paired
ALL samples
Downregulated at
relapse compared
to complete
remission in
matched-paired
ALL samples

See above [124]
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Low expression
was associated
with
poorer response to
prednisone and is a
part of a miRNA
signature used to
discriminate
between relapse
and
complete remission
Target analysis
identified c-MYC
and RAS as
downstream targets
of the let-7 family.
mRNA levels of cMYC and RAS were
upregulated in
MLL-rearranged
ALL compared to
non-MLL
B-ALL patientsa
Lowly expressed in
ALL; can be used
in miRNA
expression
signature to
discriminate ALL
from AMLi
Lowly expressed in
ALL; can be used
in miRNA
expression
signature to
discriminate ALL
from AMLi
Higher expression
correlated with
higher relapse free
survival in newly
diagnosed ALL
patients
Higher expression
correlated with
higher relapse free
survival in
newly diagnosed
ALL patients

[113]

[116],
[123]

[123,
124]

[124]

1.4.2 Autoimmunity
Autoimmune diseases represent a significant health problem in the United States
(US) and may be on the rise. After examining three time periods (1988-1991, 1999-2004,
and 2011-2012) it was reported that the prevalence of antinuclear antibodies (ANA), a
common feature of autoimmunity, was increasing among select groups in the US, including
males, adolescents, and adults over the age of 50 years [126]. Autoantibodies produced by Bcells contribute to disease progression by binding various host tissues resulting in
inflammation and triggering the activation of the immune response [127]. Consequently, Bcells are major contributors to the pathogenesis of autoimmune diseases. In an effort to block
their responses, monoclonal antibody (mAb) therapeutics functionally depleting B-cells
have been used and can be effective [128]. For example, rheumatoid arthritis (RA) patients
given Rituxan (rituximab/anti-CD20) in combination with cyclophosphamide, had
improved outcomes even after the return of B-cells at 26 weeks [129, 130]. However, these
treatments may only be beneficial for select groups as ~10% of patients did not achieve
complete B-cell depletion [131, 132]. In addition, B-cell depletion mAb are associated with
a wide spectrum of adverse reactions [131, 132]. Thus, there remains a need to identify
novel therapeutic targets and better understanding of the underlying molecular pathways
involved in B-cell function in autoimmunity.
1.4.2.1 B-cell activation in normal B-cells
Research in both human and animal models indicates that B-cell hyper -activity and
-responsiveness are central to autoimmune diseases [133]. Normal B-cell activation
requires two distinct signals: the first is antigen crosslinking to the B-cell receptor (BCR),
and the second is interaction with T-cells via the CD40-CD40L pathway. Upon antigen
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binding to BCR, CD79A and CD79B subunits will mediate subsequent signal transduction
[134]. This includes the activation of NF-kB, PI3K, MAPK, NFAT, and RAS pathways
which promote B-cell survival and proliferation [134]. CD40 signaling promotes other
downstream functions such as germinal center formation, immunoglobulin isotype
switching, and the formation of plasma cells and memory B-cells from naïve B-cells [135].
Upon BCR-stimulation, a metabolic clock begins, where B-cells have approximately nine
hours to receive costimulatory signal [136]. In the event co-stimulation is not received,
these B-cells will undergo cell death through mitochondrial induced anergic death [136].
Importantly, anergy at this stage is reversible that can be “salvaged” if co-stimulation is
received within the nine-hour timeframe. The anergic state is only entered by B-cells upon
continuous exposure of antigen through the BCR [136, 137].
1.4.2.2 Mutations in Ikaros are associated with autoimmunity
Genome-wide association studies (GWAS) have identified hundreds of gene
polymorphisms that are associated with an increased risk of developing autoimmunity.
GWAS studies performed upon genotyping 1,047 systemic lupus erythematosus (SLE)
patients identified nine new susceptibility loci, among them was IKZF1 [138]. There are
more than 30 germline heterozygous IKZF1 mutations that have been reported in
immunodeficiencies such as cytopenias, common variable immunodeficiency, and in
autoimmunity [139]. To study the link between IKZF1 variants and autoimmunity, one
group performed whole-exome sequencing (WES) of PBMCs one Belgian family [140].
The daughter in this family was diagnosed with juvenile-onset systemic lupus at the age of
12 [140]. Interestingly, both the healthy father and afflicted daughter carried a
heterozygous mutation in IKZF1 [140]. This mutation was located in the ZnF3 domain of
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IKAROS, a region that is required for DNA binding [140]. Importantly, this alteration
caused a loss of IKAROS binding to DNA, including to the CD22 gene which is known to
dampen the B-cell immune response [140]. This suggests that one possible role for
IKAROS is to upregulate the expression of CD22, and in the event IKAROS is mutated,
CD22 is depressed contributing to a lower threshold of activation [140].
The location and summary of some IKZF1 mutations described in autoimmune
patients is shown below in Table 1-4. Therefore, Ikaros has been linked to autoimmune
disease but the molecular mechanism involved in maintaining B-cell tolerance remain
elusive, representing a gap in our current knowledge.
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Table 1-4: Summary of IKZF1 mutations described in patients with an autoimmune disease
Patient
P2

Autoimmu
ne disease
Juvenileonset
systemic
lupus

Clinical
features
12y, female

IKZF1
cDNA
c.562C>G

Protein

Characteristics

p.L188V

heterozygous IKZF1
mutation, loss in DNA
binding, B-cells had
elevated Erk
phosphorylation at
baseline
heterozygous IKZF1
mutation, loss in DNA
binding, 10x-lower Bcells compared to
control but relative
frequency of B-lineage
cells was normal
heterozygous IKZF1
mutation, loss in DNA
binding, 10x-lower Bcells compared to
control but relative
frequency of B-lineage
cells was normal
heterozygous IKZF1
mutation, loss in DNA
binding
heterozygous IKZF1
mutation, caused
abnormal splicing,
predicted to impair the
function of ZnF2,
ZnF3, and ZnF4.
heterozygous missense,
loss of DNA-binding
and localization to
pericentromericheterochromatin
heterozygous IKZF1
mutation

A.1

ITP

7y, male

c.439T>C

p.C147R

D.I.1

ITP

68y, female

c.485G>A

p.R162Q

D.III.1

IgA
vasculitis

11y, female

c.485G>A

p.R162Q

E.II.1

SLE,
Evans
Syndrome

8y, male

c.589+
1G>A

Intronic,
between
ZnF3 &
ZnF4

A.I.2

Thyroitidis
Urticairia

53 y,
female

c.427C>T

p.R143
W

I.1

ITP

57 y, male

c.500A>G

p.H167R

PMID
[ref]
PMID:
29705243
[140]

PMID:
27939403
[140]

PMID:
27939403
[140]

PMID:
27939403
[140]
PMID:
27939403
[140]

PMID:
31057532
[53]

PMID:
31089937
[141]
II.1
APLS
32 y, male
c.500A>G p.H167R heterozygous IKZF1
PMID:
mutation
31089937
[141]
II.2
SLE,
24 y,
c.500A>G p.H167R heterozygous IKZF1
PMID:
APLS
female
mutation
31089937
[141]
APLS: antiphospholipid syndrome; ITP: idiopathic thrombocytopenic purpura; SLE: systemic lupus
erythematosus; ZnF: zinc finger
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1.5: Specific aims of this dissertation
1.5.1 Aim 1
To profile the tumor suppressive programs facilitated by IKAROS that may aid in
the development of novel therapeutics that target IKZF1-mutated leukemias. IKZF1
somatic deletions and missense mutations are common in high-risk-B-ALL, particularly in
cases with BCR-ABL1 translocations (up to 80%). Mutations in IKZF1 have been
associated with both poorer prognosis and a greater incidence of relapse [142]. Recent
evidence indicates that various non-coding RNAs (ncRNAs) are prognostic markers for
pre-B ALL. In our work, we generate whole-genome transcriptional profiles of two patientderived xenografts that harbor the IK-6 isoform of Ikaros and provide the altered
expression landscape upon WT IKAROS induction. We provide an mRNA-lncRNAmiRNA network for Ph+ pre-B ALL.

1.5.2 Aim 2
To determine the role of Ikaros in establishing and maintaining an epigenetic
program required for proper B-cell activation. Research in both humans and animal
models indicates that B-cell hyperactivity and abnormalities in B-cell activation are central
to these autoimmune diseases. Despite the mechanism of tolerance that normally eliminates
dangerous autoreactive immune cells, the events that lead to the aberrant activation of selfreactive B-cells in the context of autoimmunity remain unclear. In our work, we analyze
primary B-cells from a novel autoimmune mouse model containing a targeted germ-line
mutation in the Ikzf1 gene zinc finger DNA binding domain (Ikzf1ΔF4/ΔF4). Our work
characterizes the Ikzf1ΔF4/ΔF4 mouse model using an integrative approach with both
27

immunology and genomic-based techniques to understand how alterations in Ikaros
contribute to a loss of B-cell tolerance. We provide evidence that mechanistically, Ikaros
regulates two separate epigenetic mechanisms required for the regulation of geneexpression programs. The first is through the regulation of active enhancers, and the second
is through a developmental mechanism of silencing via regulation of H3K27me3 and
H3K4me3 signal. In the event of a loss-of-function deletion in Ikaros, these mechanisms
go unregulated, contributing to a break in B-cell tolerance.
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CHAPTER 2: IKAROS-REGULATED NON-CODING RNA NETWORKS IN
ACUTE LYMPHOBLASTIC LEUKEMIA

Abstract
Despite significant advances in the treatment of precursor B-cell acute
lymphoblastic leukemia (pre-B ALL), relapse is frequent and thus pre-B ALL remains a
leading cause of childhood cancer-related morbidity and mortality. Deletion of the IKZF1
gene encoding the tumor suppressor Ikaros has been identified as a recurrent mutation
associated with poor prognosis in pre-B ALL. However, the biological roles and
mechanisms of Ikaros tumor suppression in pre-B ALL are poorly understood. Using an
inducible expression system of wild-type Ikaros in IKZF1-deleted Philadelphia
chromosome positive (Ph+) pre-B ALL cells, we investigated the regulatory networks
underlying Ikaros-mediated growth inhibition in B-ALL. By integrating genome-wide
IKAROS chromatin binding analysis with comprehensive transcriptome analysis, we
identiﬁed Ikaros target genes, including long non-coding RNA (lncRNAs) and microRNAs
(miRNAs). We further examined the integrated regulatory network of lncRNAs, miRNAs,
and mRNAs and found that Ikaros targeted non-coding RNAs have the potential to regulate
critical growth suppression processes, including cell signaling and B-cell receptor
pathways. To assess this, we performed a CRISPR interference (CRISPRi) screen to
directly target 160 Ikaros-suppressed lncRNAs. We identiﬁed 12 lncRNAs required for
pre-B ALL growth, of which four could be used to stratify patients into high- and low-risk
subgroups. Overall, these results indicate that Ikaros regulates the expression of non-coding
RNAs that mediate tumor suppression functions and demonstrate an important clinical
application for improving outcome prediction for pre-B ALL.
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Introduction
Acute lymphoblastic leukemia (ALL) remains a leading cause of childhood cancerrelated mortality [1]. The majority of childhood ALL cases are of the precursor B-cell
subtype of acute leukemia (pre-B ALL) and can be further characterized by recurrent
genomic lesions, including cases that harbor the Philadelphia chromosome (Ph+) resulting
from t(9;22)(q34;q11) translocation event involving the BCR and ABL1 genes (referred to
as Ph+ pre-B ALL). Great improvements have been achieved in the diagnosis and treatment
for Ph+ pre-B ALL in the past few decades [2]. The combination of chemotherapy with
BCR-ABL1 tyrosine kinase inhibitors have been shown as effective treatments for Ph+
pre-B ALL [3]. However, despite the improved outcomes observed in childhood pre-B
ALL cases, up to 20% of patients still relapse [2]. Long-term follow-up of childhood preB ALL patients confirmed that new treatment options are required as overall these patients
have very poor prognosis despite undergoing subsequent therapy [4]. In addition, older
patients aged greater than 40 years have not greatly benefited from current treatments as
the 5-year overall survival remains lower than 43% [5,6]. Therefore, due to the high
heterogeneity of Ph+ pre-B ALL in terms of clinical and molecular features, and prognosis,
the regulatory mechanisms at the genomic level still need to be clarified.
Profiling of patient cohorts through integrative approaches has previously
identified multiple collaborating lesions, some of which are genes encoding hematopoietic
transcription factors (TFs) that are known critical regulators of B-cell development [7-10].
In Ph+ pre-B ALL patients, this includes mutations in IKZF1 (80%), PAX5 (51%), and
EBF1 (13%) genes [10,11]. Of the genes mentioned, alterations in IKZF1 have been
associated with both poorer prognosis and a greater incidence of relapse in Ph+ pre-B ALL
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[12]. A thorough understanding of the leukemic tumor suppressive programs that are
altered will be useful in the identification of novel therapeutics that target IKZF1-mutated
leukemia.
There is now emerging evidence that non-coding RNA (ncRNA) expression
signatures can serve as useful prognostic markers, define major subtypes, and act as
indicators of relapse for pre-B ALL [13-19]. Collectively, ncRNAs have been shown to
regulate a number of critical cellular processes associated with promoting disease
progression including apoptosis, cell cycle, metabolism, cell proliferation, differentiation,
and responses to chemotherapies [20-24]. NcRNAs encompass a plethora of small
regulatory RNAs including microRNAs (miRNAs), as well as tens of thousands of
polyadenylated and non-polyadenylated long ncRNAs (lncRNAs) [25,26]. The molecular
mechanisms of lncRNAs are diverse as these genes have been shown to regulate the
transcription of protein-coding genes through proximal (cis) or distal (trans) mechanisms
[27,28]. NcRNAs can influence both nuclear (i.e., DNA accessibility and gene expression)
and cytoplasmic functions (i.e., translation) of genes and proteins, and can also behave as
oncogenes or tumor suppressors in hematopoietic malignancies [29-31]. As such, ncRNAs
represent an attractive and relevant class of molecules to be investigated to identify
candidates that could be used for the diagnosis, prognosis, and treatment of Ph+ pre-B
ALL.
In this study, we provide the whole-genome transcriptional profiles of two Ph+
patient-derived xenograft cells, which harbor the IK-6 isoform of Ikaros and provide the
altered expression landscape upon wild-type Ikaros induction. This analysis provides an
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mRNA-lncRNA-miRNA network and identifies four lncRNAs that could be used to
stratify patients into high- and low-risk subgroups in pre-B ALL.

Methods
Cell culture of human patient-derived Ph+ pre-B ALL cells
Patient derived Ph+ pre-B xenograft cells (PDX2 and MXP5) were maintained at 37°C in
humidified incubator with 5% CO2 in minimum essential medium alpha (MEMα)
GlutaMAX (Gibco), supplemented with 20% FBS (Gibco). Cells were tested negative for
mycoplasma contamination and authenticated with STR profiling.

Lentiviral constructs and transduction in Ph+ pre-B ALL cells
Cloning and cell line generation was performed as described previously [32]. Briefly, full
length Ikaros isoform (IK1-GFP) and GFP-control were cloned into the TET-inducible
expression vector pLVX-TRE3G-IRES (Takara) and transduced into pre-B ALL cells
expressing TET activator pLVX-EF1a-Tet3G (Takara). Expression of wildtype Ikaros was
induced with the addition of doxycycline, a TET analog. For the CRISPRi system,
lentivirus was produced by transfecting HEK293T cells with pCMV-dR8.91 (Addgene
#2221, kind gift from Didier Trono), The BaEVTR envelope vector [32] and a transfer
vector using TransIT-LT1 reagent (Mirus) were used. The medium containing lentiviral
particles was collected 48- and 72-hours post-transfection, filtered through 0.45μM filter,
and concentrated with Lenti-X-concentrator (Clontech), then aliquoted and stored at -80
°C. Cells were mixed with lentivirus and spun down at 1000g for 30 minutes at 32 °C on
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plates coated with Retronectin (Clontech). After 48 hours, transduction efficiency was
assessed by flow cytometry.

Flow cytometry and sorting
GFP and mCherry signal was monitored using LSR Fortessa (BD). For cell cycle analysis,
cells were permeabilized with Cytofix/Cytoperm kit (BD Bioscience), stained with DAPI
and gated on GFP+. GFP+high cells were sorted for RNA-seq, CUT&RUN, and Microarray
analysis using FACS Aria II (BD). Data were analyzed using FlowJo and FACS Diva
software. For sorting of B-cell progenitors, the following cell surface markers were used
to identify subsets: Pro B (lineage-, CD34+, CD19+, CD22-), Pre BI (lineage -, CD34+,
CD19+, CD10+, CD22-), Pre-B II large (lineage-, CD34-, CD19+, CD10+, CD20mid) and
Pre-B II small (lineage -, CD34+, CD19+, CD10+, CD22-). Lineage markers used for
depletion included CD13, CD3, CD33, CD123, and CD15.

sgRNA library construction
sgRNA library was designed to contained 10 sgRNAs per gene of interest (160 guides). To
produce the sgRNA library, existing protocols were used with slight modifications [33-36].
Pool of single-stranded DNA oligonucleotides containing protospacer sequences and
adapters for PCR amplification was ordered from Twist Bioscience and amplified by PCR.
pLG21-pU6-sgRNA-EF1a-Puro-T2A-mCherry vector vas a kind gift. Insert and sgRNA
vector were digested with BstXI and BlpI (Thermo), ligated together and transformed into
XL10-Gold Ultracompetent Cells (Agilent). Thousands of colonies were scraped from
Ampicillin LB plates followed by a maxiprep.
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CRISPRi screen
Cells constitutively expressing dCAS9-KRAB were generated by transduction with
pCL0038-pHR-UCOE-EF1a-dCas9-HA-2xNLS-XTEN80-KRAB-P2A-GFP vector and
GFP+ population were sorted. dCAS9-KRAB-expressing cells were transduced with
sgRNA library lentivirus at MOI = 0.4. After 48 hours, they were selected with 1 μg/ml
puromycin for an additional 48 hours. After 24 hours, aliquot of cells at >1000x
representation was collected (day 0 timepoint). Cells were passaged regularly to keep the
concentration between 1.5-4.5x106 cells/ml and minimum of 1000 cells/guide
representation at all times. Cell pellet were then collected 30 after Day 0 (day 30 timepoint).
For both timepoints genomic DNA was extracted, PCR-amplified, and sequenced using
MiSeq platform.

Screen analysis
FASTQ files were aligned to the designed library, normalized to median and a fold change
T30/T0 for each sgRNA was calculated. Mann-Whitney U test was applied to identify
significant hits comparing individual sgRNAs fold changes for each gene to non-targeting
controls [35].

RNA isolation
RNA was isolated using the Direct-zol RNA kit (Zymo Research) following
manufacturer’s instructions. RNA was then assessed for quality with the Agilent
Bioanalyzer and quantified with the qubit fluorometer.

50

Microarray data and analysis
Purified RNA was loaded onto GeneChip™ miRNA 4.0 Array from Affymetrix. CEL files
were processed using Affymetrix Power Tools to generate log2 transformed RMA values.
The mean of 95 anti-genomic probe sets was subtracted from each summarized probe set
expression value. All probe sets with a DABG p-value > 0.05 were removed. Only probes
for 2578 human mature miRNAs were selected for further analysis. To identify mature
miRNAs, we applied Tukey’s HSD test with Benjamini and Hochberg correction for
multiple testing. The DE miRNAs (DEM) were identified according to the criteria of |log2
(fold-change) |>1 and FDR corrected P<0.05.

Construction of the miRNA-mRNA-lncRNA regulatory network
The predicted targets of the DEMs as well as the predicted targets of DE lncRNAs found
by the guilt-by-association analysis were used for network analysis. The targets of the
DEMs were identified based on the multimiR package [37]. The miRNA-mRNA-lncRNA
regulatory network was then constructed based on the predicted targets and visualized via
Cytoscape software (version 3.4.0; www.cytoscape.org).

RNA-sequencing library preparation and analysis
For RNA-Seq, 1000ng of RNA was used to prepare libraries with the NEBNext Ultra
RNA-Seq kit (Illumina) following rRNA depletion with the NEBNext rRNA Depletion kit
(Illumina). Sequencing was performed on a HiSeq1500 platform using a single-end
sequencing length of 50 base pairs. Reads were mapped to hg38 genome and read counts
were computed with HTSeq-count software [38]. Differentially expressed genes (DEG)
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were called with DESeq2 [39]. DEGs were defined as genes with an fdr lower than 0.05
and log2 fold change >1 or < -1. Clustering analysis was performed using k-means method
and Euclidian distance on log2 transformed counts. Gene Ontology pathway enrichment
analysis was performed using HypeR package [40].

CUT&RUN library preparation and analysis
CUT&RUN libraries were built using CUTANA CUT&RUN reagents and published
protocols v1.5.4 (EpiCypher) with modifications. Briefly, 0.5x106 cells frozen in 90%
FBS/10% DMSO were thawed for 2 min in a 37°C water bath, washed with Wash Buffer
(20mM HEPES, pH 7.5, 150mM NaCl, 0.5mM Spermidine, 1x Roche cOmplete, EDTAfree protease inhibitor), before incubation with activated CUTANA Concanavalin A beads
(EpiCypher). The bead:cell mix was then incubated with antibody (1:100) overnight at
4°C. After washes with Digitonin buffer (Wash Buffer + 0.01% Digitonin), CUTANA
protein AG-MNase (Epicypher) was added at a 1:20 ratio and incubated for 10 mins at RT,
followed by two additional washes. Protein AG-MNase was activated with CaCl2 added to
a final concentration of 2mM. The reaction was carried out for 3 hours at 4°C and quenched
33 µl of Stop buffer (340mM NaCl, 20mM EDTA, 4mM EGTA, 50 µg/mL RNaseA, 50
µg/mL glycogen). To release protein-DNA fragments, samples were incubated at 37°C for
10 mins and then placed on a magnet. DNA was then purified using the Monarch PCR &
DNA Cleanup kit (NEB) following manufacturer’s instructions. Libraries were constructed
using the NEBnext Ultra II DNA Library Prep Kit (Illumina) as directed with a few
modifications. To retain fragments > 150 bp after adapter ligation, a 1.1x AMPure XP bead
cleanup (Beckman Coulter) was performed. Libraries were PCR amplified for a total of 14
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cycles with cycling conditions specific for CUT&RUN (1 cycle: 45 sec at 98°C, 14 cycles:
15 sec at 98°C followed by 10 sec 60°C, 1 cycle: 1 min at 72C). The DNA was cleaned up
with 1.1x volume of AMPure XP beads (Beckman Coulter) and fragment size distribution
was assessed on DNA Bioanalyzer (Agilent). The antibodies used in this study were: rabbit
anti-Ikaros (Santa Cruz, sc-13039; clone D3015; 0.5 μg per reaction) and rabbit anti-IgG
(Epicypher, cat 13-0042; lot no 20036001-52; 0.5 μg per reaction). CUT&RUN dataset
were analyzed with CUT&RUNtools as described [41]. Briefly, FASTQ files were mapped
to hg38 reference using Bowtie 2 v2.2.9 with the –dovetail option indicated. Picard 2.8.0
MarkDuplicates was used to mark PCR duplicates. To call peaks, SEACR was used with
the stringent parameter indicated [42]. Regions bound by IgG were discarded. Regions
were annotated against hg38 using HOMER (annotatepeaks.pl). Gene ontology was
performed with GREAT [43].

Results
Induction of Ikaros in BCR-ABL1-transformed IKZF1 mutant cells results in
growth suppression and altered gene expression
To investigate the tumor-suppressor mechanism of Ikaros in pre-B ALL, we
established a TET-inducible expression system in Ph+ patient-derived pre–B ALL cells
(MXP5) expressing the dominant negative IK6 (DN-IK6) isoform (Figure 2-1A) [44].
After doxycycline stimulation, the survival of Ikaros-expressing MXP5 cells declined to
~60% while cells transduced with the GFP-control maintained nearly 100% survival
(Figure 2-1B). Importantly, in line with previous studies performed in PDX2 cells, another
Ph+ patient-derived pre–B ALL cell line, MXP5 cells similarly arrested in the G1 phase
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of the cell cycle upon induction of wt Ikaros (Figure 2-1C) [44]. Using this TET-inducible
system, we were able to recapitulate the tumor suppressor function of Ikaros in MXP5
cells, as previously shown in PDX2 cells [45].
We next set out to generate the global transcriptional profiles of both DN-IK6 preB ALL cells (MXP5 and PDX2) before and after wt Ikaros-induction. Biological replicates
for each condition were highly correlative and the principal component analysis (PCA)
revealed that although MXP5 and PDX2 cells are markedly transcriptionally distinct from
one another, both responded similarly upon wildtype Ikaros-induction (Appendix B1A,B). Differential expression analysis revealed a total of 4,472 differential genes (log2fc
>1 or <-1; padj < 0.05) that were further grouped into four distinct clusters (Figure 2-1D).
As expected, clusters 1 and cluster 2 (C1 and C2) corresponded to genes distinctly
expressed in both cell-types, regardless of wt Ikaros-induction (Figure 1D, 1412 and 1217
genes respectively). However, clusters 3 and 4 corresponded to differentially expressed
genes (DEGs) that were similarly down- or up-regulated after wt Ikaros-induction,
respectively (999 and 844 genes).
Pathways analysis of Ikaros-altered DEGs using Gene set enrichment analysis
(GSEA) revealed demethylation and lymphocyte differentiation were among the pathways
downregulated while integrin mediated signaling pathway and noncoding RNA processing
corresponded to upregulated pathways (Figure 2-1E, Appendix B-1C). Examples of genes
downregulated included mannose receptor C-Type 1 (MRC1) and CD34 (Figure 2-1F).
Ikaros has been previously shown to regulate the expression of CD34 in pre-B ALL cells
[44]. Alternatively, upregulated genes included those involved in B-cell activation (S1PR1)
and transcription factors involved in B-cell development (KLF2, SPIB, IKZF1) [46,47].
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Next, we performed upstream regulator analysis to identify transcriptional
regulators and/or other molecules predicted to regulate DEGs. Ikaros (encoded by IKZF1)
and five microRNAs (miRNAs; let-7a-5p, miR-124-3p, miR-1-3p, miR-30c-5p, miR-3383p) were among the top activated upstream regulators while NRG1, MTOR, ATF4, and
ERG were identified as the top inhibitory regulators (Figure 2-1G). Taken together, this
genome-wide transcriptional analysis revealed the conserved genes targets of Ikaros in two
Ph+ patient-derived pre-B ALL cell lines, some of which may contribute to the robust
growth suppression observed.

Ikaros regulates the expression of long non-coding RNA in Ph+ pre-B ALL
To next identify genes altered in both patient cell lines, differential analysis was
performed grouping Ph+ pre-B-cells with and without wt Ikaros induction. This analysis
now revealed a total of 2,321 DEGs (1104 up- and 1217 down-regulated). Further
investigation showed that 78.2% of DEGs were protein-coding genes while 21.8% of
altered genes were long non-coding RNAs (Figure 2-2A, and data not shown). In total, 506
DE lncRNAs (310 up- and 196 down-regulated) were identified as Ikaros-responsive and
a subset of differentially upregulated (EIF1B-AS1, U62631.1, LINC02202, MIR181A1HB)
and downregulated (AC084291.1, GAS5, AL357078.2, AL390066.2) lncRNAs are shown
(Figure 2-2B).
To determine if changes in lncRNA expression could be linked with direct Ikaros
regulation, we performed CUT&RUN for Ikaros in pre-B ALL cells. In total, we found
that Ikaros directly bound to 194/506 (38%) of deregulated lncRNAs in pre-B ALL cells.
Of these, 113/310 (36.4%) upregulated lncRNAs and 81/196 (41.3%) of downregulated
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lncRNAs were bound by Ikaros. Overall, lncRNAs that were bound by Ikaros in DN-IK6
control cells, remained bound after the induction of wt Ikaros (19.6% up- and 28% of
down-regulated lncRNAs) (Figure 2-2C). Additionally, we observed a modest increase in
the percentage of DE lncRNAs uniquely bound by Ikaros after induction (Figure 2-2C).
For example, the lncRNA BHLHE40-AS1 was among one of the highest expressed
lncRNAs with a 3.5-fold increase in expression upon Ikaros induction. The promoter of
BHLHE40-AS1 was enriched with Ikaros signal upon the induction of wt Ikaros, compared
to the GFP-control (Figure 2-2D). Alternatively, the promoter of SOCS2-AS1 had
decreased Ikaros signal (Figure 2-2D). These results indicate that Ikaros regulates the
expression of lncRNAs in pre-B ALL and of these, nearly half were directly bound, and
some promoters displayed differential occupancy of Ikaros.

Expression patterns of IK1-altered lncRNAs in healthy precursor B-cells
B-ALL develops from a genetic transformation of developing B-cells. To examine
the expression patterns of IK1-altered lncRNAs in healthy precursor B-cells, we sorted
developing B-cells from the bone marrow of healthy donors at 4 developmental stages of
B-cell development and performed RNA-seq analysis (Figure 2-3A). During B-cell
development, pro-B-cells are generally defined by the presence of CD19+ and in the next
stage, pre-BI cells express the pre-B-cell receptor (pre-BCR) while the cell surface marker
CD34 becomes significantly downregulated and remains low for the remainder of B-cell
development. The gene expression of CD19, CD34, IKZF1, and PAX5 in healthy precursor
B-cells are shown as positive controls (Figure 2-3B).
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Next, we visualized the expression of Ikaros-responsive lncRNAs in healthy
precursor B-cells (Figure 2-3 C, D). This analysis uncovered 3 distinct patterns of
expression of up- or down-regulated lncRNAs in healthy precursor B-cells, respectively
(Figure 2-3 C, D). Cluster C1 displayed the most distinct transcriptional pattern among the
upregulated lncRNAs, which became highly expressed at the preB I stage of development
(Figure 2-3C, cluster C1). Among the downregulated lncRNAs, cluster D1 corresponded
to a group of lncRNAs that were highly expressed at the progenitor B stage, however, by
the preB I stage had declined (Figure 2-3D, cluster D1). While genes in cluster D2
represented a group of lncRNAs that are highly expressed at the preB I stage, however,
decreased in expression prior to entering the pre–B II Large stage (Figure 2-3D, cluster
D2).

Identification of Ikaros-regulated miRNAs
Previously, we identified five miRNAs (miRNAs; let-7a-5p, miR-124-3p, miR-13p, miR-30c-5p, miR-338-3p) as activated upstream regulators upon Ikaros induction. To
investigate the spectrum of miRNAs expressed in IKZF1-mutated B-ALL, we extracted
RNA from independent IKZF1-mutated B-ALL samples that have been induced with IK1expression or an empty-vector control and performed miRNA microarray analysis. To
identify DE miRNAs in IK1-expressing samples compared to controls, we applied DE
analysis with Benjamini and Hochberg correction for multiple testing. This analysis
identified 21 miRNAs that were upregulated in IK1 vs. control, and 10 miRNAs as downregulated miRNAs in pre-B ALL cells (Figure 2-4A). Among the IK1-upregulated
miRNAs, we identified miR-150 as Ikaros-responsive, a critical regulator of B-cell
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development that is primarily expressed in the lymph nodes and spleen (Figure 2-4B) [48].
In B-ALL, miR-150 had been previously shown to be lowly expressed in pediatric patients
compared to healthy controls [49]. Conversely among downregulated miRNAs, we
identified miR-26b which was previously implicated in T-ALL (Figure 2-4B) [50].
Next, to explore the potential implications of IK1-regulated miRNAs in the growth
suppression of B-ALL, we performed a comprehensive in silico analysis aimed at the
prediction of mRNA targets regulated by miRNAs identified as DE between IK1 and
control cells. We took a comprehensive approach and utilized multiple target prediction
tools with data from several databases (as described Methods). Pathway analysis revealed
purine metabolism, cell cycle, and focal adhesion to be among those targeted by
upregulated miRNAs (Figure 2-4C). Conversely, pathways belonging to apoptosis, long
term potentiation, B-cell receptor signaling were targeted by downregulated miRNAs
(Figure 2-4D).

miRNA-lncRNA-mRNA regulatory networks
We next examined the miRNA-lncRNA-mRNA regulatory networks that were
altered with IK1-induction and constructed an integrated regulatory network consisting of
DE lncRNA and mRNA targets of IK1-induced and IK1-repressed miRNAs. A total of
44,368 predicted and validated mRNA targets of miRNAs were determined by the
multimiR R package. Predicted mRNA targets of DE lncRNAs were determined by guiltby-association analysis (data not shown). A total of 1,088 interactions between DE
lncRNAs and mRNAs were included (data not shown). Two separate regulatory networks
were then constructed for either IK1-induced and IK1-repressed miRNAs and their targets,
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containing 158 and 203 differentially expressed lncRNAs and mRNAs, respectively
(Figure 2-5A and 2-5B). Pathway analysis found that the IK1 regulatory networks
contained genes associated with JAK/STAT signaling pathway, p53 signaling pathway and
pathways in cancer (data not shown).

CRISPRi screen identifies 12 lncRNAs required for the survival in Ph+ pre-B ALL
cells
To assess the effect of Ikaros-dependent lncRNAs on cell growth, we transduced
Ph+ pre-B ALL cells with lentivirus containing ~2,000 sgRNAs targeting 160 lncRNAs
that were downregulated upon Ikaros-induction. Transduced cells were selected with
puromycin and kept at >1000 cells/sgRNA for 30 days. Cells were harvested at Day 0 and
Day 30, and sgRNA sequences from both timepoints, then PCR amplified and NGS was
subsequently performed. Using the Mann-Whitney U test, we determined the sgRNA
present at Day 30 and Day 0. We identified a total of 12 lncRNAs that were present in cells
at Day 0, however, by Day 30 were no longer present in Ph+ pre-B ALL cells that had
survived puromycin selection. These included 7 unique candidates in PDX2 cells
(CCDC26,

AP001318.2,

AL357078.2,

AC008622.2,

AC002350.2,

SNHG4,

AC244033.2), 4 unique candidates in MXP5 cells (SOCS2-AS1, AC015712.2, CEBPADT, AL133215.2), and one candidate (DANCR) in both Ph+ pre-B ALL cell lines (Figure
2-6A and 2-6B). Together this assay identified 12 downregulated IK-responsive lncRNAs
that upon genetic knockdown, perturbed the overall survival of Ph+ pre-B ALL cells.
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High expression of four Ikaros-responsive lncRNAs is associated with reduced
survival in 561 pre-B ALL patients
We hypothesized that high expression of the IK-responsive lncRNAs identified by
CRISPRi could be used as an indicator of poor patient outcomes in pre-B ALL. To test
this, we utilized 561 pre-B ALL RNA-Seq datasets provided by The National Cancer
Institute’s Therapeutically Applicable Research to Generate Effective Treatments
(TARGET) project to predict patient survival. The 561 patients were split into quartiles
from highest to lowest expression to produce Kaplan-Meier curves. We found pre-B ALL
patients highly expressing SNHG4 (n=103, purple) resulted in a significant reduction in
patient survival compared to the low-expressing patients (p=0.0067; Figure 2-6B).
Similarly, high-expression of CEBPA-DT (n=106; p=0.0061, purple), AC015712.2
(n=100; p<0.0001, purple) and SOCS2-AS1 (n=92; p<0.0001, purple) also resulted in a
profound impact on patient survival. Taken together, these findings suggest that high
expression of SNHG4, CEBPA-DT, AC015712.2 or SOCS2-AS1 could be used as
prognostic indicator of poorer patient survival for pre-B ALL.

Discussion
Ikaros is frequently mutated in Ph+ pre-B ALL, a high-risk subtype of ALL.
Specifically, mutations in Ikaros occur in ~80% of patients with this subtype ultimately
resulting in worse patient outcomes. In an effort to further understand the tumor-suppressor
function of Ikaros, we performed whole transcriptome analysis on two Ph+ pre-B ALL cell
lines that harbored the DN-IK6 isoform and induced the expression of wt Ikaros. This
resulted in robust gene expression changes, particularly in ncRNAs expression. Aberrant
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ncRNA expression has been previously shown to serve as prognostic indicators to predict
treatment response or disease relapse for hematologic malignancies and cancers [51].
However, as a result of the non-coding genome not being completely annotated, the
biological functions of many miRNAs and lncRNAs are unknown and more experimental
work is required to clarify clinical relevance.
In an effort to understand if Ikaros exerts its tumor-suppressor function through
modulation of ncRNA expression, we integrated our transcriptional analysis with genomewide Ikaros binding data. In total, we identified 506 Ikaros-responsive lncRNAs of which
38% were directly bound by Ikaros. We further show that a group of Ikaros-downregulated
lncRNAs are similarly downregulated in normal, healthy B-cell development, however, are
highly expressed in DN-IK-6 Ph+ preB-ALL. This finding suggests that Ikaros works to
repress the expression of these lncRNAs, however, in the event of a DNA binding deletion,
are no longer able to carry out this function.
To analyze if miRNAs are also Ikaros-responsive, we conducted microarray
analysis with IKZF1-mutated B-ALL samples that have been induced with IK1-expression
or an empty-vector control. This analysis unveiled 31- miRNAs that are up- or downregulated upon Ikaros induction. Integration of this information with the RNA-Seq analysis
performed, permitted the construction of a miRNA-lncRNA-mRNA regulatory network in
pre-B ALL cells with IK1-induction. Pathway analysis of IK1-induced regulatory networks
revealed JAK/STAT signaling, adherens junctions, and long-term potentiation were
enriched. Importantly, these networks could be used to understand ncRNAs function in BALL and aid in the development of novel therapeutics. Finally, lncRNAs previously
identified as repressed upon wt Ikaros induction were genetically targeted using genetic
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modulation. Large-scale CRISPRi of 160 lncRNAs resulted in the identification of 12
candidate lncRNAs important for pre-B ALL viability. Confirmatory analysis was
performed by utilizing publicly available RNA-seq datasets generated in 561 B-ALL
patients by The National Cancer Institute’s Therapeutically Applicable Research to
Generate Effective Treatments (TARGET) project. Our findings support the scenario that
pre-B ALL patients highly expressing four lncRNAs (SNHG4, CEBPA-DT, AC015712.2
or SOCS2-AS1) have an overall negative impact on patient survival.
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Figures
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Figure 2-1. Induction of Ikaros in BCR-ABL1-transformed IKZF1 mutant cells
results in growth suppression and altered gene expression. (A) Outline of the
experimental approach used to recapitulate the Ikaros tumor suppression. Upon addition of
the TET-analog, doxycycline, Ikaros was expressed in patient-derived Ph+ pre-B ALL
cells and RNA-seq and FACS was performed. (B) Growth curve of IK1-WT-GFP+ and
GFP-control+ cells over 12 days. (C). Cell cycle analysis by flow cytometry. (D) Heatmap
of differentially expressed genes (DEGs) (log2fc >1 or <-1; fdr < 0.05) in MXP5 and PDX2
cells transduced with GFP-control or IK1-WT-GFP. Representing two independent
experiments. (E) Top GSEA gene sets comparing GFP-control vs IK1-WT-GFP (F) Bar
plot representation of selected genes. (G) Displaying the top 15 activated or inhibited
upstream regulators identified in GFP-control vs IK1-WT-GFP.
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Figure 2-2. Ikaros regulates the expression of long non-coding RNA (lncRNAs) in Ph+
pre-B ALL. (A) MA-plot displaying differentially expressed mRNAs (blue) and lncRNAs
(red) in Ph+ pre-B ALL cells transduced with GFP-control vs IK1-WT. (B) Bar plot
representation of selected DE lncRNAs genes. (C) Bar plot representation of the percentage
of lncRNAs bound by Ikaros in Ph+ pre-B ALL cells transduced GFP-control or IK1-WT
cells. (D) Displaying Ikaros CUT&RUN peaks across the SOCS2-AS1 and BHLHE40AS1 locus in Ph+ pre-B ALL cells transduced GFP-control or IK1-WT cells.
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Figure 2-3. Expression patterns of IK1-altered lncRNAs in healthy precursor B-cells.
(A) Flow cytometry sorting scheme used to identify 4 developmental stages of B-cells
isolated from PBMCs of healthy donors. Pro B (lineage-, CD34+, CD19+, CD22-), Pre BI
(lineage -, CD34+, CD19+, CD10+, CD22-), Pre-B II large (lineage-, CD34-, CD19+,
CD10+, CD20mid) and Pre-B II small (lineage -, CD34+, CD19+, CD10+, CD22-).
Lineage markers used for depletion included CD13, CD3, CD33, CD123, and CD15. (B)
Gene expression of CD19, CD34, IKZF1, and PAX5 in healthy precursor B-cells. (C)
Heatmap of upregulated and (D) downregulated lncRNAs in healthy precursor B-cells.
RNA-seq experiments were performed for three independent experiments. Differentially
expressed lncRNAs are defined as log2fc >1 or <-1; fdr < 0.05.
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Figure 2-4. The identification of Ikaros-regulated microRNAs in Ph+ pre-B ALL. (A)
Differential expression analysis of miRNAs expressed in MXP5 and PDX2 cells
transduced with GFP-control or IK1-WT-GFP (log2fc >1 or <-1; fdr < 0.05). (B) Bar plot
representation of selected DE microRNAs genes. (C) Predicted target pathways of
upregulated miRNAs and (D) downregulated miRNAs. mRNA predicted as targets of DE
miRNAs were used for pathways analysis.
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Figure 2-5. Network analysis of Ikaros-regulated miRNA-lncRNA-mRNA. Regulatory
networks were constructed for either IK1-induced and IK1-repressed miRNAs and their
predicted targets. In total, 158 and 203 DE lncRNAs and mRNAs are represented,
respectively. Red, miRNA. Yellow, lncRNA. Purple, mRNA. Grey lines represent
downregulated DE targets. Blue lines represent upregulated DE targets.
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Figure 2-6. CRISPRi and survival analysis identifies four IK-responsive lncRNAs
that are associated with poor survival in pre-B ALL. (A) Mann-Whitney U was used to
determine sgRNA present at Day 30 and Day 0. Green=MXP5 unique, purple = PDX2
unique, red = present in both, and blue = not significant. (B) Kaplan-Meier curves of
SNHG4, CEBPA-DT, AC015712.2 or SOCS2-AS1 stratified by four groups from highest
to lowest expression: Q1 (top 25% quantile; purple), Q2 (mid 25% quantile, green), Q3
(low-mid 25% quantile, blue), and Q4 (bottom 25% quantile, red).
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CHAPTER 3: IKAROS MUTATIONS CAN LEAD TO LOSS OF B-CELL
TOLERANCE AND AUTOIMMUNITY DUE TO FAILURE TO REPRESS
DEVELOPMENTALLY REGULATED GENES
Abstract
Recent reports have described recurrent mutations in the IKZF1 gene in patients
with autoimmune diseases. Comparing two different Ikzf1-mutant mice, with deletions of
exons encoding DNA-binding zinc finger (ZnF) 1 or 4 (Ikzf1DF1/DF1 and Ikzf1DF4/DF4), we
found that the Ikzf1DF4/DF4 mutant mice have high levels of serum autoantibodies and
inflammatory cytokines at a young age. In ex vivo stimulation, wt B-cells required
costimulation for proliferation and survival, while B-cells from Ikzf1DF4/DF4 mice responded
to BCR stimulation alone. Single-cell and bulk transcriptome analysis revealed a subset of
progenitor and alternative lineage genes aberrantly expressed in Ikzf1DF4/DF4 B-cells,
including genes involved in signaling, and the aberrant activation of Ikzf1DF4/DF4 B-cell
upon BCR stimulation. Mechanistically, we found that Ikaros was required to silence
several genes during B-cell development, some of which were bivalently marked at
progenitor B-cell stage and substrates of g-secretase.

Introduction
The etiology of autoimmune disease is unknown but is believed to be due to a
combination of genetic pre-disposition and environmental factors. Genome-wide
association studies (GWAS), as well as an increasing use of next generation sequencing
(NGS) of patient samples, have provided valuable insight into potential genetic
contributing factors. The gene IKZF1, encoding the zinc finger (ZnF) transcription factor
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Ikaros has been implicated as a susceptibility gene in various autoimmune diseases through
GWAS, including Systemic Lupus Erythematosus (SLE) [1-4]. Furthermore, recent reports
have described recurrent mutations in IKZF1 in patients with autoimmune diseases, as well
as Common variable immunodeficiency (CVID) and hypogammaglobulemia [5-12]. The
point mutations described in these patients are predicted to result in loss-of-function or
dominant negative Ikaros protein, indicating a role of Ikaros in the protection against
autoimmune disease in humans.
Ikaros is expressed throughout hematopoiesis and is important for the proper
regulation of multiple immune cell lineages [13]. In particular, Ikaros null mice display a
complete lack of B lineage cells, demonstrating a critical role of Ikaros in B-cell
development [13]. We have previously created mouse models with targeted deletions of
the exons encoding the DNA-binding ZnF1 or ZnF4 (Ikzf1DF1/DF1 and Ikzf1DF4/DF4) and found
that these mice display distinct phenotypes in hematopoietic development [21]. Notably,
in contrast to the germline Ikzf1null mutant mice [13], both of these ZnF mutant mice have
mature peripheral B-cells, but at reduced levels and with partial defects at different stages
of early B-cell development. Ikzf1DF1/DF1 display a partial block at the stage of heavy chain
rearrangement (transition from pre-BI to large pre-BII), while Ikzf1DF4/DF4 display a partial
block at transition between proliferating large pre-BII to small pre-BII [14].
Herein, we describe a new mouse model of autoimmunity, and focus on the role of
Ikaros in B-cell tolerance. We show that Ikzf1DF4/DF4 mutant mice, but not Ikzf1DF1/DF1
mutant mice have high levels of autoreactive antibodies and elevated inflammatory
cytokines in serum of young mice. Furthermore, in contrast to wt B-cells which require
costimulation, Ikzf1DF4/DF4 mutant B-cells responded to ex vivo acute BCR stimulation
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alone, without the requirement for the second co-stimulatory signal. Interestingly,
Ikzf1DF1/DF1 mutant B-cells had an overall reduced response compared to wildtype.
Mechanistically, we found that Ikaros is required for proper gene program regulation
during B-cell development, including the repression of genes that are bivalently marked
(H3K27me3+/H3K4me3+) at the progenitor B-cell stage.

Methods
Mice and genotyping PCR
The Ikzf1ΔF1/ΔF1, Ikzf1ΔF4/ΔF4 mice (Schjerven et al., 2013) and CD3e-/- (Malissen et al,
1995) were on a C57BL/6 background (n ≥ 12). For all experiments described herein, 2 or
more independent experiments were performed with different biological replicates for each
experimental sample. WT C57BL/6 mice were obtained from The Jackson Laboratory.
Animals were housed by Laboratory Animal Resource Center (LARC) at UCSF. All
experiments were approved by the UCSF Animal Research Committees (ARC) and were
performed according to UCSF Institutional Animal Care and Use Committee (IACUC)
guidelines. Genotyping of mice was performed on blood by PCR with Phusion Blood
Direct PCR Master Mix (cat # F175L, Thermo Fisher Scientific) or by flow cytometry
(CD3e-/-).

Analysis of Autoreactive Antibodies
Analysis of serum autoreactive antibodies was performed with the classical HEp-2 ANA
assay (Cat # 708100, INOVA Diagnostics, Inc; and cat # FA2400EB, Zeus Scientific (cat#
21123100, Fisher Scientific)) according to manufacturer’s protocol, with the following
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modifications: Mouse serum was diluted 1:200 and the mouse IgG was detected by a
secondary AF488 labeled a-mouse IgG (Jackson Immuno Research, cat # 715-546-150) at
1:200 dilution in the presence of DAPI for nuclear stain (1:200 dilution of 50 ug/ml stock).

Cytokine analysis
All samples were treated according to the protocol following the Bio-Plex Pro TM Mouse
Cytokine 23-plex Assay (Bio-Rad cat# M60009RDPD), before being run on the Bio-PlexR
MAGPIXTM Multiplex Reader and analyzed with the Bio-Plex ManagerTM MP Software
(Bio-Rad cat# 171015001). Calibration and validation of the machine was done with the
Bio-Plex MAGPIX Calibration Kit (Bio-Rad cat# 171213001) and Bio-Plex MAGPIX
Verification Kit (Bio-Rad cat# 171213002), respectively. Serum and spleen extract
samples were diluted 1:4, while media samples from cultured cells were diluted 1:2 in
sample buffer from the kit. Spleen extracts were obtained by collection of the media in
which the spleen was dissociated into single-cell suspension, and storage at -80C until
analysis.

Ex vivo B-cell stimulation assay
Spleen leukocytes were isolated by dissociation of spleen tissue in media, followed by red
blood cell lysis, filtering (40 µm) and platelet were depleted by centrifugation at 200 ´ g
for 10 min, repeated twice. Naïve B-cells were enriched from spleen by MACS negative
depletion with the mouse B-cell Isolation Kit, according to manufacturer’s protocol (cat #
130-090-862). Purity were evaluated as %CD19+ cells post MACS. Cells were kept on ice
or 4oC during processing. Cells were counted and cultured at 106 cells per ml (105 cells in
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100 µl for 96-well assays), and either left unstimulated, or stimulated with 50ug/mL a-IgM
(1020-01, Southern Biotech) with or without 80 ug/mL CD40L ( GFM10-25, Cell
Guidance Systems). Cells were evaluated by microscopy and harvested at different
timepoints for analysis. For resazurin assay, cells/signal were/was measured by/at (Ex 560
nm, Em 590nm, protocol) on day 3 after 3.5 – 4 hours incubation with 10 ul Resazurin
(Biolegend). For cell division analysis, cells from each mouse were incubated with Tag-It
Violet cell proliferation dye according to manufacturer’s protocol (Biolegend), prior to
separating into different wells for the three stimulation conditions.

Flow cytometry
Cells were collected and processed on ice, with addition of Fc block and stained with
antibodies against either CD19, CD69, DAPI, APC live/dead, CD85K, CD3e, CD45.1, and
CD45.2. Maximum 106 cells were used per stain, and the amount of all antibodies were
tested with a default dilution of 1:100 and titrated as needed. Samples were analyzed at the
UCSF Parnassus Flow Cytometry Core, on a Fortessa (BD).

RNA isolation and library preparation for RNA-Seq
Cells were collected and lysed in TRIzol reagent (Thermo Fisher Scientific). Total RNA
was isolated using the Direct-zol RNA Kit (Zymo). A starting input of 600-1000ng of total
RNA was used for the NEBnext rRNA Depletion Kit (Illumina) and libraries were
constructed using the Ultra Directional RNA Library Prep Kit (Illumina). Libraries were
prepared with 2-3 biological replicates per condition and PCR amplified for 12 cycles.
Library size distribution was assessed on Agilent Bioanalyzer High Sensitivity DNA chip.
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RNA sequencing analysis
Sequencing was performed on a HiSeq2000 platform using a single-end sequencing length
of 50 base pairs yielding and range 18 to 51 million reads. Reads were mapped to
GRCm38/mm10 genome with STAR aligner [15] and read counts were computed with
HTSeq-count software [16]. Differentially expressed genes (DEG) were called with
DESeq2 [17]. DEGs were defined as genes with an fdr lower than 0.05 and log2 fold
change >1 or < -1. Clustering analysis was performed using k-means method and Euclidian
distance on log2 transformed. Pathway and upstream regulator analysis were performed
with Ingenuity Pathway Analysis (IPA).

Cleavage under Targets and Release Using Nuclease (CUT&RUN) Sequencing
CUT&RUN libraries were built using CUTANA CUT&RUN reagents and published
protocols v1.5.4 (EpiCypher) with modifications. Briefly, 0.5x106 cells slowly frozen in
90% FBS/10% DMSO were thawed for 2 min in a 37°C water bath, washed with Wash
Buffer (20mM HEPES, pH 7.5, 150mM NaCl, 0.5mM Spermidine, 1x Roche cOmplete,
EDTA-free protease inhibitor), and spun at 600 g at RT for a total of two washes. Cells
were incubated with activated CUTANA Concanavalin A beads (EpiCypher) and
incubated with primary antibody overnight at 4°C. Samples were washed twice with
Digitonin buffer (Wash Buffer + 0.01% Digitonin), and CUTANA protein AG-MNase
(Epicypher) was added at a 1:20 ratio and incubated for 10 mins at RT, followed by two
additional washes. Protein AG-MNase was activated with CaCl2 added to a final
concentration of 2mM. The reaction was carried out for 3 hours at 4°C and quenched 33 µl
of Stop buffer (340mM NaCl, 20mM EDTA, 4mM EGTA, 50 µg/mL RNaseA, 50 µg/mL
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glycogen). Samples were incubated at 37°C for 20 mins and then placed on a magnet to
release protein-DNA fragments. Supernatant containing fragments was transferred to a
new tube and final volume was raised to 300 µl. To extract DNA, 15 µl of DNA extraction
buffer (3 µl of 10% SDS (final concentration 0.1%), 5 µl of proteinase K (at 10 mg/ml), 2
µl RNaseA (at 1mg/ml), and 5 µl of 5M NaCl (final concentration 300mM)) was added,
vortexed,

then

placed

at

50°C

for

1

hour.

DNA

was

precipitated

by

phenol/chloroform/isoamyl alcohol followed by ethanol precipitation with glycogen and
dissolved in TE buffer. Libraries were constructed using the NEBnext Ultra II DNA
Library Prep Kit (Illumina) as directed with a few modifications. To retain fragments >
150 bp after adapter ligation, a 1.1x AMPure XP bead cleanup (Beckman Coulter) was
performed. Libraries were PCR amplified for a total of 14 cycles with cycling conditions
specific for CUT&RUN (1 cycle: 45 sec at 98°C, 14 cycles: 15 sec at 98°C followed by 10
sec 60°C, 1 cycle: 1 min at 72C). The DNA was clean up with 1.1x volume of AMPure XP
beads (Beckman Coulter) and fragment size distribution was assessed on DNA Bioanalyzer
(Agilent).

Assay for Transposase Accessible Chromatin Sequencing (ATAC-Seq)
ATAC-seq was performed on 50-80,000 cells slowly frozen overnight in 90% FBS/10%
DMSO (n=2) as described previously [18]. In detail, frozen cells were thawed for 2 min in
a 37°C water bath, mixed with PBS (1:1), and centrifuged at 2,000 rpm for 5 min at 4°C.
The supernatant was removed, and pellets were washed once with cold PBS (1:1),
centrifuged at 2,000 rpm, and resuspended in 50 µl of cold cell lysis buffer (10 mM PIPES
pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 0.1% TritonX-100). The cells were
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incubated on ice for 5 min and spun at 2,500 rpm for 5 min at 4°C. Next, 1 mL of ATACresuspension buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2) containing
0.1% Tween 20 was added and samples were centrifuged at 2,500 rpm at 4°C for 5 min.
The nuclear pellets were resuspended in 20 µl transposition reaction mix. Each reaction
contained 10 µl of 2X TD buffer (Illumina, San Francisco, CA), 0.8 µl of TDE1 (Illumina,
San Francisco, CA), and 9.2 µl of water and were placed on a shaker at 1,000 rpm for 30
mins at 37°C. Tagmented DNA was purified with the MinElute PCR purification kit
(Qiagen, Frederick, MD) and eluted in 10 µl. Samples were PCR-amplified using
NEBNext High-Fidelity 2x PCR Master Mix (NEB) and indexed with Nextera Indexing
primers (Illumina). Double-sided bead cleanup (0.55X/0.5X) was performed using
AMPure XP beads (Beckman Coulter). Quality of libraries was checked with Bioanalyzer
(Agilent) and quantified with Qubit dsDNA HS assay kit (Agilent).

ATAC-Seq data analysis
Samples were pooled at equimolar ratios and sequenced on NovaSeq platform using 80-bp
paired end sequencing. The transposase adapters were trimmed with Cutadapt v.1.13 (-q
10 -m 15 -e 0.1) and mapped to GRCm38/mm10 genome using Bowtie2 [19] with --very
sensitive --maxins 2000 --no-discordant --no-mixed parameters indicated. Duplicate reads
were removed with Picard Tools and reads mapping to chrM were excluded. Peaks were
then called using MACS2 v.2.1.1 (--nomodel --keep-dup all -p 0.01 --shift 0 --extsize) [20].
For biological replicates, only concordant peaks with an IDR threshold of less than 0.1
were kept and used for downstream analysis. DeepTools v.2.5.1 was used to generate

84

bigWig tracks with a --binSize 25 --normalizeUsing RPKM --extendReads options
indicated.

Results
Ikzf1DF4/DF4 mutant mice have high levels of serum autoantibodies at young age
Based on emerging reports that linked mutations in the IKZF1 gene with human
autoimmune disease, we analyzed serum from the Ikaros-mutant mice for the presence of
autoantibodies, which is a hallmark of autoimmune disease. Serum from Ikzf1DF1/DF1,
Ikzf1DF4/DF4 and control mice were tested by indirect immunofluorescence to determine
whether they were positive for antinuclear antibodies (ANA) by adaptation of the clinical
diagnostic Hep2 ANA assay to detect mouse IgG. Serum from Ikzf1DF4/DF4 mice, as young
as 5 weeks of age, had intense nuclear staining, comparable or stronger than serum from
6-month-old Lyn-/- or Fas/lpr mice used as positive controls [21,22] (Fig. 3-1a and data not
shown). Notably, all Ikzf1DF4/DF4 mice tested at 5-6 weeks of age displayed strong Hep2ANA positive signal, suggesting 100% penetrance. In contrast, Ikzf1DF1/DF1 mice did not
show any sign of ANA, even at an older age. To investigate the potential role of T cells in
the observed young onset of serum ANA, we crossed the Ikzf1DF4/DF4 mice with Cd3e-/- mice
that lack all peripheral T cells [23]. We found that Ikzf1DF4/DF4;Cd3e-/- mutant mice
displayed elevated serum ANA when compared to Ikaros wild-type Cd3e-/- littermate
controls, although at lower levels than Ikzf1DF4/DF4 mice with T cells, indicating that
autoreactive B-cells developed in the absence of T cells (Fig. 3-1b).
Antibodies against double-stranded DNA (dsDNA) is one of the most common
auto-antigens recognized in patients with SLE [24-26]. Analysis of a-dsDNA antibodies
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by ELISA showed that Ikzf1DF4/DF4 mice had elevated IgG a-dsDNA antibodies as well as
IgM in their serum, although serum from Ikzf1DF4/DF4 mice displayed relative lower levels
of dsDNA auto-antibodies than the serum from Lyn-/- and Fas/lpr mice, used as positive
controls [27-29] (Fig. 3-1c, Appendix C-1a). Notably, the Ikzf1DF1/DF1 serum did not display
autoantigen reactivity above the wt controls for neither IgM nor IgG (Fig. 3-1a,c,d). To
determine the overall level of serum Ig subtypes, we analyzed Ab subclass types by ELISA.
We found that the Ikzf1DF4/DF4 mice had increased levels of the pro-inflammatory IgG2a,
while the a-inflammatory IgG3 was reduced relative to wt and Ikzf1DF1/DF1 (Fig. 3-1e and
Appendix C-1b).

Ikzf1DF4/DF4 mutant mice have reduced MZ B-cells and increased Age-associated Bcells
The high levels of autoreactive antibodies in the serum of Ikzf1DF4/DF4 mice
suggested autoimmunity with B-cell involvement. As previously reported, Ikzf1DF1/DF1 and
Ikzf1DF4/DF4 mice have peripheral B-cells, but at reduced levels as compared to wt [14].
Analysis of the peripheral B-cells in the spleen revealed changes in the composition of
splenic B-cell compartments between wt and Ikaros-mutant mice. Notably, there was an
increase in CD23-neg;CD21-neg/low;CD19+ Age-associated B-cells (ABCs) in the Ikzf1DF4/DF4
mice relative to wt, while this was not observed in the Ikzf1DF1/DF1 mice (Fig. 3-2a,b).
Interestingly, the Marginal zone (MZ) B-cells were greatly reduced in Ikzf1DF4/DF4 mice,
and significantly increased in Ikzf1DF1/DF1 mice (Fig. 3-2a,b). There were no significant
differences in Follicular (Fo), germinal center (GC), IgG isotype-switched, or
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CD180+;CD81+ B-cells (encompassing the Memory B-cells) in the spleen of the Ikarosmutant mice (Fig. 3-2a,b and Appendix C-1c).

Mice harboring deletion of Ikzf1 zinc finger 4 exhibit signs of systemic inflammation
Based on the observations of early onset high levels of autoreactive antibodies in
Ikzf1DF4/DF4 mice, we next analyzed serum cytokine levels and found that Ikzf1DF4/DF4 mutant
mice had significantly higher levels of the inflammatory cytokines IL-6, IL-12/IL-23(p40)
and IL-12(p70) than wt and Ikzf1DF1/DF1 mutant mice (Fig. 3-2c). In addition, IL-2, G-CSF,
KC, IL-5, IL-10, and MIP-1a was also elevated in the serum of Ikzf1DF4/DF4 mutant mice
(Fig. 3-2c and Appendix C-2a). Both IL-6 and IL12/IL23-p40 are clinical therapeutic
targets with FDA approved blocking antibodies for different inflammatory or autoimmune
diseases [30, 31]. Interestingly, MIP-1a (CCL3) is a chemokine secreted by B-cells upon
Ag recognition through binding of Ag to their B-cell receptor (BCR) [32]. Due to the
spontaneous development of thymic lymphoma in Ikzf1DF4/DF4 mutant mice [14], we were
not able to investigate old Ikzf1DF4/DF4 mutant mice for autoimmune-associated end-organ
disease. However, we did observe the presence of C3 deposits in glomeruli in kidneys from
some 13-16-week-old Ikzf1DF4/DF4 mutant mice (Appendix C-2b). Together, our findings
indicate immune dysregulation in the Ikzf1DF4/DF4 mutant mice, with high levels of systemic
autoreactive antibodies, with autoreactive B-cells developing also in the absence of T cells.

B-cells from Ikzf1DF4/DF4 mice respond to Ag alone, without the need for a costimulatory signal

87

The early onset and high level of serum ANA in the Ikzf1DF4/DF4 mice suggested a
break of B-cell tolerance. Normally, a productive B-cell response to antigen is restricted
by a requirement for a co-stimulatory signal [33-37]. To evaluate the requirement for costimulatory immune signals in B-cells from Ikaros-mutant mice, we isolated untouched
splenic naïve B-cells by magnetic bead negative depletion from wild-type, Ikzf1DF1/DF1 and
Ikzf1DF4/DF4 mice and cultured these B-cells for three days in the presence of a-IgM alone,
or with a-IgM and CD40 ligand (CD40L) as a co-stimulatory signal (Fig. 3-3a). In this ex
vivo stimulation assay, we observe cell blasting and cell clumping after 24h stimulation,
while cell division does not start until after 48 hours (data not shown).
Comparing the B-cells from wt and Ikaros-mutant mice, we next assessed
responsiveness through the resazurin assay after 3 days of stimulation, which measures
proliferative and metabolic responses through the reduction of resazurin into resorufin.
Both wild-type and Ikaros-mutant B-cells responded to co-stimulation with a-IgM +
CD40L (Fig. 3-3b). As expected, wt B-cells did not respond to a-IgM alone, supporting
the requirement for a second co-stimulatory signal. Similarly, Ikzf1DF1/DF1 B-cells also did
not respond to a-IgM alone and displayed a significantly lower signal than wt for the aIgM + CD40L co-stimulation, suggesting that Ikaros ZnF1 is required for proper responses
of these B-cells (Fig. 3-3b). In contrast, we found that Ikzf1DF4/DF4 B-cells did not require
CD40L but responded strongly to a-IgM alone (Fig. 3-3b).
Analysis of cell division after 3 days of stimulation confirmed that both wild-type
and Ikzf1DF1/DF1 B-cells required both a-IgM and CD40L to proliferate, whereas Ikzf1DF4/DF4
B-cells proliferated with a-IgM alone (Fig. 3-3c). Again, the Ikzf1DF1/DF1 B-cells exhibited
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reduced response with a-IgM + CD40L co-stimulation as compared to wt cells (Fig. 3-3c).
To investigate the potential role of T cells in the observed break of B-cell tolerance, we
analyzed the splenic B-cells from Ikzf1DF4/DF4;Cd3e-/- mice that lack all peripheral T cells
[23]. The ex vivo stimulation of spleen B-cells from these Ikzf1DF4/DF4;Cd3e-/- mice revealed
a similar result where Ikzf1DF4/DF4 -mutant B-cells proliferated in response to a-IgM alone,
even if they had never encountered T cells (Fig. 3-3d). Taken together, these results
indicate that although T cells are likely to contribute to the overall autoimmune reaction in
Ikzf1DF4/DF4 mice, the break in B-cell tolerance develops independent of T cells.
Looking at earlier response at 24 hours, we found that Ikzf1DF4/DF4 B-cells induced
robust expression of the activation marker CD69 in response to a-IgM alone, while wt Bcells required a co-stimulatory signal to obtain this level of CD69 expression (Fig. 3-3e).
This was also observed in B-cells from Ikzf1DF4/DF4;Cd3e-/- mice (data not shown). In
agreement with aberrant activation of Ikzf1DF4/DF4 B-cells, a-IgM alone was sufficient to
induce the secretion of stimulation-induced cytokines in culture supernatants from
Ikzf1DF4/DF4 B-cells, including chemokines Mip-1a and Mip-1b as well others (Fig. 3-3f).
Furthermore, examination of cytokine levels from Ikzf1DF4/DF4 mutant mice spleen extracts
demonstrated significantly higher levels of Mip-1a and Mip-1b compared to spleen
extracts from wild-type mice, in addition to elevated levels of IL-4, IL-13, KC and IFN-g
(Fig. 3-3g and Appendix C-3).
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Aberrant activation by a-IgM is intrinsic to Ikzf1DF4/DF4 B-cells, and is not transferred
to bystander wt B-cells
One possible explanation for the observed aberrant a-IgM B-cell reaction is if the
Ikzf1DF4/DF4 B-cells produce extracellular molecules that confer a second costimulatory
signal. To test this, ex vivo stimulation assays were performed with co-cultured CD45.1+
wt B-cells and CD45.2+ Ikzf1DF4/DF4 B-cells. We found that wt B-cells stimulated by a-IgM
alone did not display the robust cell proliferation that was observed for the Ikzf1DF4/DF4 Bcells in the same well (Fig 3-3h). This indicates that Ikzf1DF4/DF4 B-cells do not proliferate
with a-IgM alone due to production of a cell-extrinsic second co-stimulatory signal. In
some experiments, we observed a mild positive effect on the wt CD45.1 B-cells in the aIgM stimulation condition when cultured together with Ikzf1DF4/DF4 B-cells (data not
shown). However, the co-culture condition was not sufficient to enable proliferation of the
wt cells to the same extent as the Ikzf1DF4/DF4 B-cells in the same well in response to a-IgM
alone, or as compared to the same wt cells when receiving co-stimulation. While extrinsic
secreted factors or cell surface molecules from the Ikzf1DF4/DF4 B-cells might play a positive
role in B-cell response, they are not sufficient to allow robust response of wt B-cells.
Overall, these results indicate that B-cell intrinsic factors are required for the Ikzf1DF4/DF4
break in B-cell tolerance.

Dynamic transcriptional response during early B-cell Activation
To investigate the differences between wt and Ikzf1DF4/DF4 B-cells, we established
differential gene expression profiles of wt and Ikzf1DF4/DF4 naïve B-cells and their
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transcriptional responses upon BCR activation. Splenic naïve B-cells were isolated as
above (Fig 3-3a) and RNA sequencing (RNA-seq) was performed following 6 hours of
stimulation with a-IgM or a-IgM + CD40L, with three independent biological replicates.
The 6 hour timepoint was chosen to capture the early responses for cellular commitment
upon B-cell activation, prior to a-IgM-induced cell death [136].. These results revealed
6,305 differentially expressed genes (DEGs) for wt and Ikzf1DF4/DF4 spleen B-cells after
performing all pairwise comparisons across the 3 ex vivo conditions (Fig 3-4a). Clustering
revealed that 53.8% of DEGs were altered due to ex vivo stimulation (Fig 3-4a: clusters 1
and 3). Importantly, the Ikzf1DF4/DF4 mutant B-cells responded similarly as wt B-cell upon
activation by both signals (a-IgM and CD40L), both in magnitude and in direction (Fig. 34a; clusters 1 and 3). Pathway analysis of genes responsive to a-IgM/ a-IgM+CD40L
treatment (clusters 1 and 3) revealed enrichment in a number of pathways including B-cell
activation and ribonucleoprotein pathways (Fig. 3-4b). The expression of RNA-binding
protein genes has been previously shown to increase in expression upon B-cell activation
and are important for other B-cell functions [38-41]. Transcriptional responses due to aIgM stimulation in naïve Ikzf1DF4/DF4 B-cells were directly compared to that of wt B-cells
(Appendix C-4a; 2410 and 1718, respectively). Overall, the overlap of gene expression
changes due to a-IgM in naïve Ikzf1DF4/DF4 B-cells were similar to wt B-cells and correlated
well with other published datasets (Appendix C-4) [42].
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Ikzf1DF4/DF4 mutation results in the deregulated baseline expression of a subset of genes
in mature B-cells
The most prominent difference between wt and Ikzf1DF4/DF4 expression pattern
belonged to untreated cells. In particular, cluster 2 and 5 represented 31.2% of all DEGs
and were expressed lower or higher in unstimulated wt or Ikzf1DF4/DF4 B-cells (Figure 3-4a,
673 and 1299, respectively). In total, 1,031 up- and 174 down-regulated genes were
deregulated in Ikzf1DF4/DF4 cells when directly compared to wt B-cells at the unstimulated
state (Appendix C-4c; log2 fold-change > 1, p-adj value < 0.05). Gene set enrichment
analysis (GSEA) revealed that unstimulated Ikzf1DF4/DF4 B-cells have an increased
expression of immune signaling gene pathways including leukocyte chemotaxis, KRAS
signaling, ERK 1/2 cascade, and IL6/JAK-STAT3 immune pathways with decreased
expression in RNA export, processing, and localization pathways (Appendix C-4f).
Together these results indicate that resting Ikzf1DF4/DF4 B-cells have deregulated expression
programs that may contribute to the derailment of tolerance following BCR-stimulation.

A subset of genes is deregulated in Ikzf1DF4/DF4 B-cells upon stimulation with a-IgM
alone
Pairwise comparison of Ikzf1DF4/DF4 cells stimulated with a-IgM to wt B-cells
stimulated with a-IgM identified 550 deregulated genes (Appendix C-4d). To narrow the
subset of genes that may be linked to the altered proliferative response demonstrated by
Ikzf1DF4/DF4 cells, the 550 altered a-IgM genes were overlapped with the wt BCRresponsive genes previously identified (Appendix C-4a). This revealed a smaller subset of
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genes (196 total) that displayed five distinct patterns of expression (Fig. 3-4c). Notably,
genes in clusters 1-3 were upregulated in response to a-IgM in Ikzf1DF4/DF4 B-cells and had
no or lower expression in wt B-cells, even in the presence of a-IgM (Fig. 3-4c). These
genes belonged to pathways such as negative regulation of phosphorylation, focal
adhesion, and response to external stimulus (Fig. 3-4d). Among these were Lilr4b and
Lilrb4a, encoding two cell surface proteins that together create the cell surface protein
CD85k (Fig. 3-4e). The selective upregulation of CD85k by a-IgM alone in Ikzf1DF4/DF4 Bcells was confirmed at the protein level by flow cytometry (Fig. 3-4f). Of note, pathogenic
plasma cells in patients with SLE have been reported to express high levels of CD85k,
although the biological significance of this is not yet known [43]. Furthermore, we noticed
multiple cell surface molecules implicated in cell signaling among the genes upregulated
by a-IgM in Ikzf1DF4/DF4 B-cells in subclusters 1-3, such as Axl, Igf1r, Ryk, Flt1 and Nrp1.
The expression of Nrp1 was confirmed to be upregulated by a-IgM alone at the protein
level in Ikzf1DF4/DF4 B-cells (Fig. 3-4g).

Single-cell transcriptomics reveal enrichment of distinctive splenic B-cell populations
in Ikzf1DF4/DF4 mice
Our RNA-seq results indicated that the gene expression programs of resting
Ikzf1DF4/DF4 B-cells differed from that of wt B-cells. While bulk RNA-seq captured the
population average, it failed to capture the complex heterogeneity of single cells. To enable
the identification of altered spleen B-cell subsets, we profiled single cell gene expression
in Ikzf1DF4/DF4 and wt resting B-cells isolated from the spleens of 6-week-old mice using
droplet-based single cell RNA-sequencing (scRNA-seq). This allowed us to investigate if
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the observed deregulated genes in Ikzf1DF4/DF4 B-cells were representative of i) homogenous
deregulation in all Ikzf1DF4/DF4 B-cells, or if they represented ii) heterogenous
subpopulations of Ikzf1DF4/DF4 B-cells that aberrantly expressed different subsets of the
observed deregulated genes (Fig 3-5a). In total, we profiled 17,684 wt cells and 19,043
Ikzf1DF4/DF4 B-cells, with an average of 1,147 genes detected per cell. We integrated both
datasets using 2000 anchor genes to use for dimensionality reduction and embedding with
the uniform manifold approximation (UMAP), as well as for unsupervised cell clustering.
We identified 12 distinct clusters of cells in this analysis. Among which the main cluster
encompassing 81.9% of the total cells (cluster 1) was balanced in cell cluster composition
when comparing wt and Ikzf1DF4/DF4 datasets (Fig. 3-5 a,b). Consistent with the isolation
protocol, the majority of cells expressed the B-cell marker genes including CD19 (60.9%
of all cells), CD79a (94.3% of all cells), and CD79b (92.4% of all cells) (Fig. 3-5c).
However, several of the smaller clusters (clusters 3-8) were overrepresented in Ikzf1DF4/DF4
compared to wt (Fig 3-5b).
To validate cluster identity, we used the top 30 cluster-defining genes to generate a
similarity score of all immune cell populations found in the ImmGen gene expression
database [44]. We confirmed seven B-cell clusters (clusters 1 through 7), one restricted
potential progenitor cell cluster (cluster 8) and four myeloid-lineage clusters (clusters 9
through 12) resembling dendritic cells and macrophages in secondary lymphoid organs
(Fig. 3-5d). Further investigation of cluster 7 revealed a distinct transcriptional profile
characterized by high expression of genes involved in cell cycle (Bub1b, Cdc25b, E2f1,
Ccnb1), as well as transcriptional repressors (Ezh2, Gfi1b, Creg1). It is known that Ikaros
promotes the expression of Gfi1, a paralog of Gfi1b, and attenuates PU.1 expression in
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MPPs [45]. A heatmap with the top 50 DE genes per cluster (fdr < 0.05 and expressed in
at least 30% of cells within the cluster) and examples are shown (Fig. 3-5e; Appendix C5). Overall, we observed that B-cells isolated from wt and Ikzf1DF4/DF4 spleens were mostly
a homogeneous group of cells. However, a small group of cells with a transcriptional
signature similar to restricted potential progenitor B-cells was identified and characterized
at the single-cell level.

ATAC-seq reveals differential accessible regions between wt and Ikzf1DF4/DF4 that
correlate with observed deregulated gene expression
To determine the altered chromatin accessibility in Ikzf1DF4/DF4 B-cells from wt Bcells, B-cells either left unstimulated or stimulated with a-IgM for ATAC-seq analysis. We
included analysis of a-IgM treated cells to interrogate the early changes in chromatin
accessibility induced in BCR-stimulated B-cells and included two independent biological
replicates. To delineate how epigenomic dynamics govern the transcriptional responses to
a-IgM in wt and Ikzf1DF4/DF4 B-cells, we identified all statistically significant differential
accessible sites (DARs; fdr < 0.05). This analysis uncovered a total of 616 DARs across
the genome (497 elements change between wt and Ikzf1DF4/DF4 and 119 elements change
with a-IgM) and identified four distinct accessibility clusters (C1 to C4) via unsupervised
hierarchical clustering and observed two key patterns (Fig 3-6a). First, there were regions
corresponding to patterns of chromatin accessibility and gene expression in response to aIgM treatment, revealing an opening and closing of 106 and 13 elements similar in both wt
and Ikzf1DF4/DF4 B-cells (Fig. 3-6a: clusters C1 and C2). Second, the most predominant

95

difference in DARs corresponded to regions changing between wt and Ikzf1DF4/DF4 left
unstimulated, with 69 regions having higher accessibility in wt B-cells, and 428 regions
more accessibility in Ikzf1DF4/DF4 B-cells (Fig. 3-6a). Similarly, the expression of DARassociated genes corresponded well with alterations in chromatin accessibility.
Next, we examined the DNA motifs associated with DARs. While cluster C2 had
too few peaks to perform meaningful analysis, motif analysis of the DNA sequences
enriched in the differentially accessible regions in cluster C1 revealed an enrichment for
the transcription factors RUNX1 and ETV1, which are known to be involved in early Bcell development. Interestingly, cluster C3, which was associated with reduced expression
in Ikzf1DF4/DF4 spleen B-cells, was enriched in motifs for Ikaros, Nanog, and Hic1
suggesting a positive regulatory role of Ikaros in the expression of these genes. Cluster C4,
representing regions more accessible in Ikzf1DF4/DF4 B-cells, was enriched for a composite
PU.1/IRF8, SpiB, and Fra1. These factors are known to be important for the development
of follicular and germinal center (GC) B-cells [46,47]. Pathways corresponding to genes
annotated in DARs are shown (Figure 3-6b).

Ikzf1DF4/DF4 B-cells display an overall altered enhancer landscape
To uncover the potential epigenetic mechanism observed between the correlating
DARs and altered gene expression, we generated CUT&RUN data sets for active
chromatin marks (H3K4me1, H3K4me3, H3K27ac, and H3K9ac) and the repressive
chromatin mark H3K27me3 in both Ikzf1DF4/DF4 and wt B-cells. Consensus peak sets
between biological replicates were identified for both wt and Ikzf1DF4/DF4 for each mark.
Analysis revealed a total of 2,898 sites differentially marked (log2fc >1 or < -1; fdr < 0.05)
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upon comparing wt and Ikzf1DF4/DF4 chromatin for each mark. The differential elements
were grouped into 12 clusters (I-XII), each of which had varying combinations of
H3K4me1, H3K27ac, H3K27me3, H3K4me3, and H3K9ac (Fig. 3-6c). Binding of wt
Ikaros was secluded to regions in cluster 4 and 10, enriched in H3K27ac, H3K4me3, and
H3K9ac. However, regions lacking Ikaros binding could be indirectly regulated by Ikaros
or represent changes in chromatin established by Ikaros at earlier stages of development.
Strikingly, the largest difference in differential elements corresponded to clusters VI-VIII
when combined accounting for nearly half of all altered sites (Fig. 3-6d). We further
annotated the differential elements for all clusters to the nearest gene and applied Gene
Ontology (GO) term enrichment analysis using GREAT v3.0.0. GO analysis of cluster VI
revealed genes enriched in pathways for B-cell receptor signaling and Systemic Lupus
Erythematosus in B-cell signaling pathway (Fig. 3-6e). Together these studies show that
alterations in Ikaros result in dramatic enhancer reprogramming, of which alterations occur
at genes involved in B-cell receptor signaling and Systemic Lupus Erythematosus
responses.

Ikaros is required for proper developmental gene regulation
The largest group of DEGs were those upregulated in Ikzf1DF4/DF4 B-cells at baseline
compared to wt B-cells, indicating that Ikaros plays a role in the repression of these genes
in mature B-cells. To gain further insight into the normal regulation of these genes, we
analyzed the expression of this subset of DEGs at an earlier stage of B-cell development.
This analysis revealed 7 distinct patterns of expression of which, 47.4 % were not
expressed in wt mature B-cells nor in wt progenitor B-cells (clusters 2, 6, 7) (Figure 3-7a).
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Accordingly, upon inspection of the chromatin at the TSS of the DEGs for clusters 2, 6, 7
we found that the H3K27me3 signal was higher in wildtype B-cells compared to
Ikzf1DF4/DF4 B-cells (Figure 3-7a). However, different from cluster 2, genes in clusters 6 and
7 were highly expressed in Ikzf1DF4/DF4 progenitor B-cells (Figure 3-7a). Chromatin patterns
at these clusters were both marked with high H3K4me3 and H3K9ac signal compared to
wt (Figure 3-7a).
To investigate this further and uncover the mechanisms underlying the regulation
of genes derepressed in Ikzf1DF4/DF4 B-cells, we analyzed published Cap Analysis of Gene
Expression sequencing (CAGE-seq) from wt progenitor and mature B-cells
(PMID:22669466). This analysis revealed three patterns expression, 1) DEGs silenced
from progenitor B to mature B-cells (+/-CAGE to -CAGE), 2) DEGs silent in both
progenitor B and mature B-cells (-CAGE to -CAGE), and 3) DEGs activated in both
progenitor B to mature B-cells (+/-CAGE to +CAGE) (Fig. 3-7b). Confirming our findings
above, we found that 43.4% of DEGs were not expressed in progenitor B or mature Bcells. Further, inspection of chromatin revealed that genes silenced normally from the
progenitor to mature B stage, had increased H3K4me3+ signal when compared to wt,
indicating a failure to silence these genes in the Ikzf1DF4/DF4 mutant B-cells. Notably among
these, we found a group of genes (App, Cdh5, Efnb2, Igf1r, Pcdhgc3, and Ryk) that were
known substrates of g-secretase [48,49]. The chromatin profile across Igf1r is shown (Fig.
3-7d). Treatment with g-secretase inhibitor resulted in the amelioration of the hyperproliferative responses observed in Ikzf1DF4/DF4 B-cells stimulated with costimulation alone
(Fig. 3-7e).
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Discussion
Herein, we present a new mouse model of monogenic autoimmunity. The
Ikzf1DF4/DF4 mutation allows for development of mature B-cells and has 100% penetrance
of phenotype at young age with high serum levels of a-nuclear antibodies (ANA) and
bypass of peripheral B-cell tolerance checkpoint with aberrant response to a-IgM alone.
These findings support that Ikaros regulates the response to acute BCR signal in mature Bcells, and that defects in Ikaros function can lead to break of tolerance and aberrant B-cell
response to BCR signaling without co-stimulatory signal. This is supported by recent
reports where conditional deletion of Ikaros at the mature B-cell stage led to the
development of systemic inflammation and autoimmunity [50]. While the role of Ikaros at
the mature B-cell stage is also supported by recent conditional deletion of Ikaros in mature
B-cells, our model has allowed for the discovery of a novel and important role for B-cell
tolerance of Ikaros in the transition between progenitor B-cells and mature B-cells.
Conditional deletion of Ikaros at the progenitor B-cell stage (by mb1-cre) blocks B-cell
development and does not allow for mature B-cells to arise [51].
On the other hand, conditional deletion of Ikaros at the mature B-cell stage leads to
defect in regulation of chronic signal and autoreactivity that is dependent upon T cells [50].
This latter model is in agreement with our findings but does not capture the defect in
restricting acute BCR stimulation, the T-cell independent aspects of B-cell tolerance, or
the developmental defects in gene regulations that our model has allowed us to uncover.
Thus, our Ikzf1DF4/DF4 model captures the complex deregulation at multiple stages of B-cell
development and provides novel insight into the multiple roles of Ikaros in restricting Bcell responses and safeguarding against autoimmunity.
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Our comprehensive analysis of transcriptome and chromatin status with ATAC-seq
and key histone modifications (H3K4me3, H3K27ac, H3K4me1, H327me3, H3K9ac)
revealed two scenarios of Ikaros requirement in the regulation of B-cell tolerance. The first
is through the regulation of active enhancers (H3K4Me1+, H3K27ac+) which comprises
~40% of all differential sites that correspond with open chromatin and altered gene
expression. In the second, we find a defect in silencing of a set of genes during B-cell
development. Our data supports the hypothesis that Ikaros is required for the removal of
the H3K4me3 mark to silence bivalently marked genes in the transition from progenitor Bcells to mature B-cells to enforce a proper gene expression program. Known g-secretase
substrates were identified as both epigenetic (H3K27me3+, H3K4me3+) and
developmentally regulated from the progenitor B to mature B stage (CAGE+ to CAGE -).
Thus, the aberrant activation of Ikzf1DF4/DF4 B-cells could be restrained upon the inhibition
of g-secretase signaling.
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Fig. 3-1. Ikzf1DF4/DF4 mice have high levels of serum autoreactive antibodies.
a,b Anti-Nuclear autoantibodies (ANA) in serum from 6 week old mice analyzed by Hep2 ANA assay, stained with DAPI (blue) and a-mouse-IgG secondary Ab (green). Wt,
Ikzf1DF1/DF1 mice and Ikzf1DF4/DF4 mice (b) and CD3e-/-;Ikzf1wt/wt with littermate CD3e-/-;
Ikzf1DF4/DF4 mice in c, a-dsDNA IgM and IgG Ab in serum from 9-16-week-old mice by
ELISA. d, Serum Ig subclass levels by ELISA from 6-week-old mice. Ikzf1DF4/DF4 mice
have increased levels of IgG2A (left), and decreased levels of IgG3 (middle) and IgA
(right). Results in a are representative of ten or more independent experiments, and analysis
in b-d was performed in two (b,c) or three (d) different experiments. Significance was
analyzed with one-way ANOVA with Bonferroni * P ≤ 0.05; ** P ≤ 0.01
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Fig. 3-2. Ikzf1DF4/DF4 mice display signs of systemic inflammatory response.
a,b, Flow cytometry analysis of CD19+ spleen B-cells were analyzed with CD21 and CD23
to distinguish Follicular B-cells (FO), Marginal Zone B-cells (MZ) and Age-Associated Bcells (ABC). c, Ikzf1DF4/DF4 mice have significant increased levels of the indicated cytokines
in serum from 6-week-old mice. Data points represents biological replicates, with the mean
(b) or mean and SEM (c) indicated. Analysis in a-c was performed in 3 or more different
experiments, and significance was analyzed with one-way ANOVA with Bonferroni (b) or
the multiple t-test Kruskal-Wallis (c). * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤
0.0001.
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Fig. 3-3. Spleen B-cells from Ikzf1DF4/DF4 mice display aberrant activation by a-IgM
alone, without requirement for a second co-stimulatory signal and occur in the
absence of T cells.
a. Schematic of experimental workflow b-f, Spleen B-cells enriched by negative depletion
(MACS) from 6-week-old mice were incubated without stimulation (u), with a-IgM alone
or a-IgM+CD40L and analyzed by Resazurin assay at day 3 (b), flow cytometry with cell
division tracking dye at day 3 (c,d), by flow cytometry analysis of CD69 at 24h (e), f-g,
Bio-Plex analysis of Mip-1a and Mip-1b in culture supernatant from cultures outlined in
(a) harvested at day 3 (f) and in spleen extracts from 6 week old mice (g) . h, Ex vivo
stimulation with mixed culture of spleen B-cells from CD45.1+ wt B-cells (solid lines with
filled colors) mixed 50:50 with either CD45.2+ wt (top panel) or CD45.2+ Ikzf1DF4/DF4 Bcells (bottom panel) with analysis of cell division at day 3. b-i are representative of 3 or
more independent experiments, significance was analyzed with t-tests. * P ≤ 0.05; ** P ≤
0.01; *** P ≤ 0.001; **** P ≤ 0.0001.
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Fig. 3-4. RNA-Seq analysis of stimulation-dependent gene expression in wt and
Ikzf1DF4/DF4 B-cells.
a, Clustered heatmap of differentially expressed genes (DEG) in any pairwise comparison
from wt and Ikzf1DF4/DF4 naïve B-cells cultured ex vivo for 6 hours without stimulation, with
a-IgM or with a-IgM+CD40L. Plotted values are the mean z-scores of replicates. Mean
aggregated profiles per cluster are represented in line plots to the right. b, Biological
Process Gene Ontology enrichment of each cluster in (a), the 5 most statistically significant
results for each cluster are shown. c, Clustered heatmap of DEG upon comparing wt
without stimulation and wt stimulated with a-IgM overlapped with pairwise comparison
of wt stimulated with a-IgM and Ikzf1DF4/DF4 stimulated with a-IgM. d, Biological Process
Gene Ontology enrichment of each cluster in (c), e, Bar graphs of RNA expression (CPM)
of selected DEG. f,g Flow plot of CD85k vs CD69 and NRP1 on B-cells from wt and
Ikzf1DF4/DF4 naïve B-cells cultured ex vivo for 24 hours without stimulation, with a-IgM or
with a-IgM+CD40L. Data in a-g are representative of three independent experiments.
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Fig. 3-5. Single-cell transcriptomics reveals enrichment of distinctive splenic B-cell
populations in Ikzf1DF4/DF4 mice
a, Cellular populations in splenic wt and Ikzf1DF4/DF4 mice are identified. UMAP projection
of 17,684 wt cells and 19,043 Ikzf1DF4/DF4 B-cells are shown in 12 clusters. Each dot
represents a single cell. b, cell cluster composition from (a) are shown c, expression level
of Cd19, Cd79a, CD79b, and BCR complex is shown d, heatmap with the top 50 DE genes
per cluster (fdr < 0.05 and expressed in at least 30% of cells within the cluster) and are
shown.
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Fig. 3-6. Genome-wide analysis of chromatin shows an altered chromatin landscape
and extensive enhancer reprogramming occurring in Ikzf1DF4/DF4 B-cells
a, Heatmap of z-scores at 616 differential accessible regions (DARs) in any pairwise
comparison from wt and Ikzf1DF4/DF4 naïve B-cells cultured ex vivo for 6 hours without
stimulation or with a-IgM. Mean aggregated profiles per cluster are represented in line
plots to the right. Motifs identified using Homer. b, Pathways identified with Ingenuity
Pathway Analysis that corresponds to (a) are shown c. Heatmaps were generated by Kmeans clustering from CUT&RUN for histone modifications (H3K27ac, H3K4me1,
H3K27me3, H3K4me3, H3K9ac). A total of 12 clusters (I-XII) were identified.
Corresponding ATAC-seq signal and Ikaros CUT&RUN is shown. d, Pie chart displaying
percentage of total for I-XII. e, GO BP for Group VI are shown. Data in a-f are
representative of two independent experiments.
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Fig. 3-7. Subset of derepressed baseline genes are developmentally regulated and
addition of g-secretase inhibitor blocks the aberrant activation of Ikzf1DF4/DF4 B-cells
by a-IgM alone.
a, Clustered heatmap of differentially expressed genes (DEG) from wt and Ikzf1DF4/DF4 Bcells (mature) is shown in progenitor wt and Ikzf1DF4/DF4 B-cells. Bar plots are representing
replicate z-scores from heatmap shown in (a). Corresponding signal from histone
modifications (H3K27me3, H3K4me3, and H3K9ac) are shown. b, DNAase (DHS+/-) and
CAGE-Seq (CAGE+/-) signal of derepressed baseline DEGs from progenitor B to mature
B stage. c, H3K27me3, H3K4me3, and Ikaros signal for three categories identified are
shown. d, CUT&RUN (H3K27ac, H3K4me1, H3K27me3, H3K4me3, H3K9ac, Ikaros),
ATAC-seq, and CAGE-seq at the Igf1r locus are shown. e, Flow plot of cell division
tracking dye in B-cells from wt and Ikzf1DF4/DF4 naïve B-cells cultured ex vivo for 3 days
without stimulation, with a-IgM or with a-IgM+CD40L in absence or presence of gammasecretase inhibitor (ELND006). Data in a-e are representative of two independent
experiments.
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CHAPTER 4: CONCLUDING REMARKS
Alterations in the Ikaros result in deficiencies in the lymphoid lineage [1].
Considering that both germline and somatic mutations in IKZF1 are associated with various
immunodeficiency disorders and hematological malignancies, this dissertation studies the
altered molecular mechanisms resulting from both mutation types and contribute to the
manifestation of B-cell related disorders. Herein, I focused on Ph+ precursor B-cell ALL
and Autoimmunity. In CHAPTER 2, I investigate the altered transcriptional landscape in
two human Ph+ patient-derived xenograft cells harboring the dominant negative Ikaros
isoform (DN-IK6), a common occurrence in Ph+ preB-ALL patients [2]. I then compare
the transcriptional profile of DN-IK6 cells prior to and following WT Ikaros induction,
with the goal to study the tumor-suppressor mechanism of Ikaros in Ph+ pre-B ALL. In
CHAPTER 3, I uncover the altered epigenetic and chromatin landscape in an autoimmunelike murine model harboring a germ-line deletion in the fourth zinc finger (Ikzf1ΔF4/ΔF4) that
is hyper-responsive to BCR-stimulation; thus, displaying a break in central tolerance.
Somatic mutations in IKZF1 (80%) occur in Ph+ pre-B ALL and are associated
with worse patient outcomes [3-5]. While it has been known that Ikaros functions as a
tumor suppressor in B-ALL, the molecular mechanisms underlying this protective role
remain unclear. In this dissertation (CHAPTER 2) we use a TET-inducible system to
recapitulate the tumor suppressor function of Ikaros. Upon doing so, we generated wholetranscriptome profiles of two Ph+ pre-B ALL cells that harbored DN-IK6. Our studies
show that Ikaros-induction results in an altered transcriptional landscape, of which ~20%
resulted in aberrant non-coding RNA expression. Non-coding RNA molecules are diverse,
tissue and cell specific, and have low conservation between human and mice [6]. Thus,
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our system permitted us to test the hypothesis that Ikaros may exert its tumor suppressor
mechanism via regulation of ncRNAs and is directly applicable to humans. Of note,
although both Ikaros and noncoding RNAs have been studied extensively in pre-B ALL,
only one study exists that links Ikaros with altered non-coding RNA expression in this
disease [7]. Our findings suggest that Ikaros functions in the regulation of miRNAlncRNA-mRNA network in Ph+ pre-B ALL (CHATPER 2).
Ikaros is able to regulate gene expression by various mechanisms, including
through direct binding or recruitment of chromatin remodeling complexes [8]. In the event
of a deletion in Ikaros, studies have shown Ikaros isoforms bind to different sites [9,10]. In
agreement with these findings, our studies show that the induction of wt Ikaros in pre-B
ALL results in a modest increase in binding to Ikaros-responsive lncRNAs (CHAPTER 2).
However, more thorough follow-up studies must be performed to accurately delineate if
Ikaros binding genome-wide in pre-B ALL followed the same trend.
Of importance, increasing evidence has emerged demonstrating that microRNAs
function as critical regulators of B-cell development. For example, Li and colleagues have
shown that epigenetic silencing of miR-125b is required for normal B-cell development
[11]. Our studies identify 31 Ikaros-responsive miRNAs in Ph+ pre-B ALL (CHAPTER
2). Further investigation uncovered the miRNA-lncRNA-mRNA network altered as a
result of inducing the expression of wt Ikaros in leukemic cells. These results can serve to
unravel the complex crosstalk occurring between altered ncRNAs and as a powerful tool
to explore the molecular mechanism of molecules in B-cell leukemia.
Accordingly, our next step was to target lncRNAs previously identified as repressed
upon wt Ikaros induction (CHAPTER 2). Genetic modulation with large-scale CRISPRi of
121

160 lncRNAs resulted in the identification of 12 candidate lncRNAs as important for preB ALL viability. These candidate viability genes were identified as such if following
knockdown, cell death ensued after 30 days of puromycin selection. We next performed
confirmatory tests to explore lncRNAs expression on survival by taking advantage of
publicly available RNA-seq data generated in 561 B-ALL patients by The National Cancer
Institute’s Therapeutically Applicable Research to Generate Effective Treatments
(TARGET) project. Our findings support the scenario that pre-B ALL patients highly
expressing DANCR and SOCS2-AS1 have a negative impact on patient survival. Followup studies with chemical inhibitors targeting these candidate lncRNAs would be an
important and natural next step.
Ikaros is a hematopoietic transcription factor that regulates both gene expression
programs and associated chromatin landscape required for lymphoid development.
Chromatin deregulation arising from Ikzf1 mutations may cause an imbalance in posttranslational histone modifications, such as acetylation or methylation, that contribute to
impaired B-cell functions and predisposition to autoimmune diseases [12]. Further, it is
known that complete loss of Ikzf1 expression results in a complete block of B-cell
development. As shown previously (CHAPTER 3), germline-mutations in ZnF4
(Ikzf1ΔF4/ΔF4) result in differential alterations to the chromatin landscape. These include the
opening of chromatin sites, not normally accessible in wt B-cells, which annotated to genes
belonging to integrin pathways and receptor signaling. Importantly, these alterations
correspond to differences in gene expression programs after comparing Ikzf1ΔF4/ΔF4 to wt
transcription.
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Our data also strongly support an immense reprogramming in the enhancer
landscape, comprising of ~40% all differential marked regions, following comparison of
wt and Ikzf1ΔF4/ΔF4 chromatin (H3K27ac+, H3K4me1+) (CHAPTER 3). Ikaros has been
previously implicated as a potent regulator of super enhancers in high-risk leukemias [13].
Here, we found an obvious increase in chromatin accessibility at sites annotated as active
enhancers only found in Ikzf1ΔF4/ΔF4 (CHAPTER 3). This result suggests that a potential
mechanism of epigenetic regulation facilitated by Ikaros to maintain central tolerance, is
through the regulation of enhancers. However, we did not find that Ikaros was enriched at
these sites suggesting alternative factors may be recruited. Motif analysis of these sites
found motifs for the transcription regulators TCF7L2 and ERG were enriched (data not
shown). An interesting follow-up would be to perform genome-wide chromatin binding
assays for these factors to evaluate occupancy at the active enhancers identified.
Here, we also show that Ikaros is required to suppress the gene expression of
bivalent marked genes, some of which are both developmentally regulated and substrates
of g-secretase, to prevent hyperresponsive BCR-stimulation (CHAPTER 3). Historically,
g-secretase inhibitors are most commonly used in the treatment of Alzheimer’s disease as
there is an accumulation of amyloid β-protein precursor (APP) to form the amyloid βprotein

(Aβ)

in

the

brain

[14].

Interrogation

of

bivalently

marked

(H3K27me3+/H3K4me3+) promoters, that were CAGE- in wt mature B-cells, revealed a
group of genes cleaved by g-secretase (Cdh5, Efnb2, Igf1r, Pcdhgc3, and Ryk) including
App as uniquely altered in Ikzf1ΔF4/ΔF4 B-cells. Treatment with g-secretase inhibitor resulted
in the amelioration of the hyper-proliferative responses observed in Ikzf1DF4/DF4 B-cells
stimulated with co-stimulation alone. Together these findings imply that coordination of
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BCR-and g-secretase signaling pathways results in uncontrolled BCR-activation. In an
effort to modulate this, Ikaros functions to regulate both an epigenetic and chromatin
landscape to silence the expression of g-secretase substrates.
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Appendix A: A guided‐inquiry investigation of genetic variants using Oxford
Nanopore sequencing for an undergraduate molecular biology laboratory course

Abstract
Next Generation Sequencing (NGS) has become an important tool in the biological
sciences and has a growing number of applications across medical fields. Currently, few
undergraduate programs provide training in the design and implementation of NGS
applications. Here, we describe an inquiry-based laboratory exercise for a college‐level
molecular biology laboratory course that uses real-time MinION deep sequencing and
bioinformatics to investigate characteristic genetic variants found in cancer cell-lines. The
overall goal for students was to identify non-small cell lung cancer (NSCLC) cell-lines
based on their unique genomic profiles. The units described in this laboratory highlight
core principles in multiplex PCR primer design, real-time deep sequencing, and
bioinformatics analysis for genetic variants. We found that the MinION device is an
appropriate, feasible tool that provides a comprehensive, hands-on NGS experience for
undergraduates. Student evaluations demonstrated increased confidence in using molecular
techniques and enhanced understanding of NGS concepts. Overall, this exercise provides
a pedagogical tool for incorporating NGS approaches in the teaching laboratory as way of
enhancing students' comprehension of genomic sequence analysis. Further, this NGS lab
module can easily be added to a variety of lab-based courses to help undergraduate students
learn current DNA sequencing methods with limited effort and cost.
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Introduction
The first complete draft of the human genome was finished in 2003, initiating a
period of rapid advancement in our knowledge of the role of genomic variation in human
disease. Developments in next generation sequencing (NGS) technologies has laid the
framework for expanding genetic research and has opened up an entire industry of new
diagnostic applications. Notable new diagnostic tests are now being widely used in the
clinical setting and are contributing to our understanding of diverse diseases. In particular,
various NGS-based applications are aiding in the understanding of the pathogenesis and
progression of cancer. Genomic sequence analysis can inform distinctive responses to
drugs (pharmacogenomics) and the various mechanisms underlying different types of
cancer. Genomic knowledge therefore permits more personalized health care as NGSbased analytical approaches are becoming increasingly relevant to all medical and
biomedical professionals [1-3]. Educating the next generation of physicians, pathologists,
biomedical, and laboratory scientists will be instrumental in the workforce development
necessary for the continued delivery and advancement of genomic medicine. With reduced
costs in real-time sequencing, new opportunities exist for the application of NGS in the
teaching laboratory. However, there remains a challenge in implementing cost-effective
contemporary diagnostic tools in the undergraduate teaching laboratories.
The introduction of NGS to undergraduates interested in pursuing careers in the
biomedical sciences presents an opportunity to integrate active ‘wet-lab’ experiences with
bioinformatics analysis to promote the analytical skills required for the inquiry of data
output from the sequencer. Strong evidence exists to suggest that immersing students in a
hands-on and investigative learning experience leads to better student outcomes [4]. While
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there are several examples of integrating genomic data, gene expression and Sanger
sequencing data in the classroom, to date there are few guidelines available for laboratory
instructors interested in bringing NGS technology into the classroom. There are also
several considerations that must be accounted for prior to establishing an NGS-friendly
module in the teaching laboratory including, 1) the time required to generate and sequence
libraries, 2) analysis and interpretation of bioinformatically-heavy sequencing data, and 3)
high-cost associated with running next generation sequencing machines. Finally, the 2019
coronavirus pandemic has introduced a new hurdle for laboratory instructors which
includes executing a college-level molecular biology module off-site, to encourage
distance-learning. For the purpose of introducing NGS concepts in molecular pathology,
we created a four-week laboratory module that highlights variant detection in cancer cells
using an affordable, applicable NGS technique, which can be fulfilled with a mix of in
person and remote/online experiences.
The MinION sequencing platform introduced by Oxford Nanopore Technologies
in 2014, offers many advantages over second-generation sequencers making it an optimal
teaching tool [5]. The MinION operates by using a nanometer wide protein pore that allows
single DNA or RNA molecules to pass through. As these molecules cross, the unique
current measurement for each nucleotide is recorded and translated into sequence
information in real-time [6-7]. The MinION device is portable, easily interfaces with a
laptop, and has a startup investment estimated at ~$1,000 [8]. In addition, the MinION has
been used for clinical applications such as summarizing the gut metagenome of head and
neck cancer patients, detecting structural variants in pancreatic cancer cell-lines, and
assessing the TP53 mutational status in chronic lymphocyte leukemia patients [9-11]. The
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reasonable cost and ease of use, together with a wide range of applicability, make the
MinION sequencing device an ideal platform for the teaching laboratory.
Here, we present a molecular laboratory course exercise that combines both wetlab experimentation and variant interpretation after sequencing on the MinION platform.
The overall goal for student groups was to correctly identify an unknown non-small cell
lung cancer (NSCLC) cell-line based on its unique genomic profile. Students isolated and
then PCR amplified genomic DNA from NSCLC cells using primers they created to
amplify known variants in KRAS, EGFR, and TP53 [12-16]. Each forward and reverse
primer was tagged at the 5’ end with a unique 12-nucleotide molecular index and combined
into a single reaction to develop a multiplex PCR genotyping assay that can be interpreted
through bioinformatics analysis. These unique index tags or barcodes allowed for each
group to combine their reaction products into a single sample that was then sequenced in
real-time on the MinION device during the laboratory session. Following data processing
by demultiplexing, the step where the barcode information is used to generate unique
sequence files from each group after being sequenced together, and alignment of each file
to a reference genome sequence, students were able to interpret variants via annotation
using the freely available Integrative Genomics Browser software [17]. We show that our
students were able to accurately detect characteristic variants in three NSCLC cell-lines.
Further, we provide pre-laboratory assignments (see Supplemental Material) for each unit
that can be easily modified by instructors as needed. Overall, this four-week module can
be implemented at a low-cost, with minimal bioinformatic background, using available
equipment from a molecular biology laboratory.
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Materials and Methods
Class structure
The course, “Applied Molecular Biology Laboratory” was open to senior undergraduates
or graduate students enrolled in the Medical Laboratory Science program at the University
of Vermont. Twenty undergraduates and four graduate students were registered for the
course. The course met once weekly for 3 hours per session. For the duration of the fourweek module, students worked in groups of three and were asked to take turns during
hands-on experimentation.

Cell Culture
HCC827 (CRL-2868), H1975 (CRL-5908), and H441 (HTB-174) lung cancer cell-lines
were purchased from the American Type Culture Collection (ATCC, Manassas, VA,
USA). Cell-lines were cultured in RPMI-1640 medium with 10% fetal bovine serum and
1% penicillin-streptomycin. All cells were cultured at 37°C and 5% CO2. Cultured cells
were counted and resuspended to a final concentration of one million cells per milliliter.
One million cells were aliquoted into 1.5 mL tubes, washed once with PBS, and the cell
pellets were stored in the -80°C. These steps were not performed by the students but were
a part of the pre-laboratory preparation.

Genomic DNA extraction and Quantification for PCR
Genomic DNA was isolated by students from thawed cell pellets using the GeneJet
Genomic DNA Purification Kit (Thermo Fisher Scientific, USA) as instructed by the
manufacturer for adherent cells. All DNA pellets were eluted in 200 ul of distilled water.
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The concentration of the DNA was determined by students using a NanoDrop-2000
(Thermo Fisher Scientific, USA).

PCR and amplicon sequencing
PCR was performed by students against two regions of the human EGFR gene and one
region of the human KRAS, TP53, and GAPDH gene. Primers were designed to amplify
regions containing known variants in NSCLC cell-lines [12-16]. Forward and reverse
primers were tagged at the 5’ end with a unique 12-nucleotide sequence designed using
Barcode Generator [18]. The minimum number of mismatches between tags was set to 6bp
[19]. Each group was given their own unique combination of tagged forward and reverse
primers for each target. The primers and the expected amplicon sizes are shown in Table
1. The 50 ul PCR reactions were performed using AccuPrime Pfx DNA polymerase
(Thermo Fisher Scientific, USA) with two-step cycling conditions. Initial denaturation was
performed for one cycle at 95C for 2 minutes followed by denaturation/annealing/extension
for 25 cycles at 95C for 15 seconds and 68C for 1 minute, respectively. Students then ran
12 ul of PCR-amplified DNA in an 1.5% agarose gel. As two or more groups received the
same starting DNA material, representative samples from each cell-line were chosen for
sequence analysis to ensure read depth required for variant detection. Thus, the remaining
38 ul of a set of 12 total amplicons (4 gene regions for each cell-line) were selected for
pooling. Fragments below 150 bp were removed using a 0.9X bead cleanup with Ampure
XP beads (Beckman Coulter, USA) and eluted in 20 ul of water. The final sequencing pool
submitted for Oxford Nanopore 1D ligation for long-read sequencing was quantified at
222.8 ng/ul.
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Data analysis
Raw data sequencing data in the form of a FASTQ file was retrieved from the MinION
sequencing run and transferred to the UVM Vermont Advanced Computing Core (VACC)
for bioinformatic analysis. The NanoPack software tools were used to calculate the
sequencing run metrics (Table 2) [20]. FASTQ files were used to align raw sequence reads
against the GRCh38 human reference genome using BWA-MEM [21]. Aligned reads were
then sorted and indexed using SAMtools [22] and visualized with IGV [17].

Data Availability
The sequence data from this study have been submitted to the NCBI Short Read Archive
(https://www.ncbi.nlm.nih.gov/sra/) under accession number PRJNA668750.

Results
Module overview: Cancer variant detection through MinION amplicon sequencing
A new inquiry-based curriculum was designed and implemented for a molecular biology
laboratory course at the University of Vermont with the overall goal to help students learn
and apply practical NGS sequence analysis. In this project, senior level students generated
and analyzed DNA sequences of known gene polymorphisms from unknown NSCLC cellline samples. To support in the learning process outside of the laboratory, we developed a
set of core teaching units to provide students with an introduction to nucleic acid analysis
and variant detection using NGS technologies and bioinformatics sequence analysis
(Figure 1). The four units included: 1) primer design for multiplex targets 2) PCR
amplification and purification of amplicon targets 3) MinION sequencing, and 4) data
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analysis. Each unit was accompanied by a corresponding pre-laboratory exercise and the
project culminated in an oral and written report where students were asked to identify
unknown NSCLC samples based on genotype information.

Unit 1: Primer design for dual-index PCR amplification
The primary goal of the introductory unit was to offer students the opportunity to learn and
apply PCR primer design that would be used to amplify target genomic loci of interest.
Accordingly, students were provided with a table of genes and variants of interest in a
prelab tutorial (see Supplemental Material) on how to design PCR primers using the freely
available Benchling software suite [23]. The Benchling platform enables database
searching to retrieve gene sequence and annotation, as well as, use of the Primer3 software
to perform primer design to capture each target of interest [24]. Specifically, our students
were asked to design target primers at specific genetic loci according to NSCLC genotypes
(i.e., EGFR, TP53, KRAS) (see Supplemental Material, Supplemental Table 1). The
primers designed by students amplified approximately 1000 bp of genomic DNA
containing the genomics variants of interest (Table 1). Each group was then assigned a 12nucleotide group-specific DNA sequence as a barcode to incorporate into dual-index
primer pairs. A list of the 12-nucleotide molecular barcodes to be added to the 5’ end of
each primer is provided (see Supplemental Material). Each index primer averaged 37nucleotides in length and the average cost per primer was $7.50.
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Unit 2: Genomic DNA extraction and multiplex PCR
The second unit of this module focuses on the PCR method, including the extraction and
quantification of genomic DNA as a PCR template, preparation of working primer
dilutions, and setting up individual or multiplex PCR reactions. The prelab material
provided for this unit included a brief tutorial on the methods and principles of DNA
extraction and quantification, as well as, the protocol used to perform primer dilutions for
PCR (see Supplemental Material). In the laboratory, students extracted genomic DNA from
frozen cell pellets from NSCLC cell-lines labeled ‘A’, ‘B’ or ‘C’ (sample identities were
blind to students). Students then quantified the total genomic DNA yield of each sample
via the Nanodrop-2000 spectrophotometer. The typical yields of genomic DNA isolated by
students was 20 ng/μl with a 260/280 absorbance range of 1.8 - 2.5 (see Supplemental
Material, Supplemental Figure 1).
Each group then made primer dilutions and used the genomic DNA sample as a template
for both single target and multiplex PCR reactions (Figure 2a). A positive control primer
set was provided to the entire class which targeted the GAPDH gene and routinely
produced a distinctive 296 bp PCR amplicon. A negative control reaction which lacked
genomic DNA was also included by each student group. Each student group had a distinct,
non-redundant, index sequence added to the 5’ end of the PCR primers used (Figure 2b).
This dual indexing strategy was utilized for the purpose of identifying student group
samples during the downstream bioinformatic analyses.
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Unit 3: PCR analysis, clean-up, and MinION sequencing
The third unit focuses on the generation of the pooled amplicon library, derived from the
classes’ multiplex PCR products, to be sequenced on the MinION platform in real-time.
The prelab for this unit provided background information and instructions on how to
perform DNA gel electrophoresis, PCR purification, and amplicon quantitation for pooling
(see Supplemental Material). Following interpretation of the DNA agarose gel, students
performed PCR purification with magnetic beads and DNA quantification with the Qubit
fluorometer. Group amplicons were pooled with all other samples and used for loading a
single-use MinION Flongle flowcell as a live in-class demonstration (Figure 2c). To
maximize student engagement, student groups were asked to submit questions to be
answered during the question-and-answer period of the demonstration.

Unit 4: Bioinformatic analysis of sample genotypes
The final unit began with an overview and detailed explanation of the bioinformatic
analysis process and file conversion steps performed by instructors after receiving
sequencing data (Figure 2d). In total, the MinION sequencing run produced 310,500
sequencing reads covering 232,217,962 bases (Table 2). Following demultiplexing of
sequence reads based on dual-indexes, we found that each amplicon was overall
proportionately represented in the sequencing run (Figure 3a). The read length distribution
showed reads spanning from 350 bp to 850 bp with an average read length of 747.9 base
pairs and PHRED score of 8.5 (Figure 3b). All amplicons mapped to their expected
regions. The scripts used for file conversions, alignments, and quality control are provided
in the Supplemental Materials.
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Each student group was provided with the sequencing results in the form of a BAM and
BAI index files which were then used to perform variant analysis with the freely available
Integrated Genome Viewer (IGV) software [17]. The Unit 4 prelab distributed contained a
tutorial on how to load the human genome and BAM files for visualization in IGV (see
Supplementary Material). Students were asked to identify and annotate if mutations at the
specified genomic locations occurred when compared to the hg38 reference sequence.
Upon examining gene alignments, student groups identified their assigned NSCLC cellline based on the genomic profile. For example, groups that began with an HCC827 cells
were able to visualize a characteristic 15-bp deletion found in exon 19 of the EGFR gene
(Figure 4a), while groups that analyzed samples derived from H1975 cells were able to
visualize the R273H mutation in TP53 gene (Figure 4b).

Assessment of Student Work
Learning Assessment
As individuals working in the biomedical laboratory fields require a strong background in
scientific communication, we chose to evaluate students using both oral and written
assessments. Therefore, in addition to the pre-laboratory assignments that accompanied
each unit, this four-week module culminated to a final project accounting for 25% of the
course grade. The project continued to foster group work, through a group oral presentation
to be presented to the entire class. In addition, individual student learning was evaluated
through a 3-page written summary.
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For the oral portion, each student group was allotted a total of 15 minutes (12 minutes for
the presentation and 3 minutes for questions). All student groups were instructed to
incorporate the following during their presentations:
1.

A broad overview of the analysis and data used for genotyping the NSCLC
samples.

2. Describe the normal function of the genes that were mutated and why these specific
genes are considered diagnostic in cancer.
3. Identify and describe if these two genes are altered in other cancers.
4. Read and describe a primary reviewed journal article that incorporated a NSCLC
cell-lines to study one of the genetic alterations identified.
For the 3-page written summary, in addition to answering the questions above, students
were asked to include the purpose of the research undertaken in the journal article selected
and to summarize the results and major findings of the study.
Individual student participation was assessed by instructors as follows:
1. Each student was asked to submit a peer evaluation form for each group
presentation.
2. Question(s) queried by the student during the question portion of the group
presentation.
The rubric used to evaluate the group presentations and a summary of select written
feedback provided by students is shown (see Supplemental Material, Supplemental Table
3). Finally, to accommodate students with documented learning disabilities, students were
permitted to pre-record their 12-minute presentation to be viewed by the entire class, as
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well as, submit questions to be answered at a later time by writing them down on an index
card and submitting them to the instructor after the session ended.

Student Perception Survey
During the final week of classes, students were given a 5-question survey to determine
student perception after completing this module. Out of the 24 students enrolled in the
course, 18 completed the evaluation. In total, 83% and 94% of students reported this was
their first time learning about the MinION sequencing platform and IGV, respectively
(Table 3). After participating in the laboratory, a total of 38% and 60% of students reported
feeling more comfortable than not to prepare samples for MinION and to independently
use IGV for the purpose of genetic variant analysis, respectively. Finally, 50% of students
reported to improve upon their knowledge in NGS technologies after participating in this
four-week module.
Some students also provided general comments about their experience participating in this
four-week module. Students commented it was an overall ‘positive lab experience’ and
‘loved that the module had a purpose’. However, some students did comment that at times
the instruction felt ‘rushed’. As a suggestion, a couple of students recommended spending
more time, before starting ‘hands-on’ work, on the background or with the assignment
tutorials provided.

Discussion
In this article, we present an accurate, specific and sensitive multiplex PCR reaction
that can be sequenced in real-time on the MinION platform to provide students with
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inquiry-based hands-on learning of DNA sequence-based diagnostic tests. In the past, there
were many barriers to overcome by instructors who sought to incorporate DNA sequencing
into the teaching laboratory curriculum. With the advent of third generation sequencing
platforms, DNA sequencing has become more accessible for a greatly reduced cost. The
results reported here serve as proof-of-concept that MinION sequencing can be
implemented in the teaching laboratory for the purpose of cultivating scientific inquiry and
providing experience for methods used in contemporary molecular biology.
We provide a four-week module with a week-to-week guide including assignments
that cover primer design, multiplex PCR, sample preparation, and entry-level
bioinformatics to be used in the molecular biology laboratory class setting. Using MinION
sequencing, all student groups were able to correctly identify the NSCLC sample they were
assigned, based on its unique genomic profile. The MinION system was able to produce
the data in the time frame of a single class. The size and ability of the MinION to easily
hook-up to a laptop allowed us to feature an in-class demonstration where students watched
sequencing occur live. Students then used this data to detect both deletions and single
nucleotide polymorphisms characteristic to lung cancer samples. To adapt to distancelearning, the MinION demonstration could be easily broadcasted and streamed online by
instructors. Importantly, the raw data is available on NCBI and therefore, a majority of this
lab exercise could be adapted for an entirely remote laboratory experience.
In conclusion, the MinION system allowed for the detection of genetics variants in
non-small cell lung cancer cell-lines. By implementing this four-week module students
were able to take ownership in the design and sample preparation required for NGS
sequencing. This module serves as a useful tool for instructors which could be formatted
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to accommodate a non-BLS2 (Biosafety Level 2) laboratory and modified for off-site
learning. Furthermore, many outcomes were achieved as a result of this laboratory module.
First, student independence and proficiency were enhanced by allowing them to design and
test their own PCR primers. Second, students were introduced to advanced molecular
assays including multiplex PCR and NGS sample preparation, in addition to computational
experience in a practical introductory manner. Finally, this module can be effectively
incorporated into a molecular biology curriculum as it could function to enhance genetic
variant analysis and core concepts in molecular pathology and oncology. This NGS-based
module is an easily implementable way to introduce a wide range of students to
contemporary molecular biology techniques and bioinformatics, and also serves as a
springboard for interested students to pursue further training in research and medical
diagnostics.
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Table A-1. Target specific primer sequences used for PCR amplification

Gene
KRAS
GAPDH
EGFR15
del
EGFR
TP53

Forward sequence (5’ - 3’)

Reverse sequence (5’ - 3’)

GGACCCTGACATACTCCC
AAGG
TTCCGGAAACCAGATCTC
CCAC
TGTGGCACCATCTCACAA
TTGC
TAATGGTCAGCAGCGGGT
TACA
TTCTTCTTTGGCTGGGGA
GAGG

AAGCGTCGATGGAGGAGT
TTGT
AAACCTGGGGGAATACGT
GAGG
AACAATACCCATGCTCCA
GGCT
GGGCCTTTCCTGTTCCTTA
GGT
CCCCTCCTCAGCATCTTAT
CCG

160

Amplic
on size
(bp)
544
296
462
721
1400

Table A-2. Data summary of MinION sequencing run
Parameter measured

Mapped

Mean read length

747.9

Mean read quality

8.6

Median read length

506

Median read quality

8.5

Total number of reads

310,500

Read length N50

760

Total bases

232,217,962
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Table A-3. Student evaluation of the four-week module (n = 18)
Definitely
True

More true
than false

In between

More false
than true

Definitely
False

%

n

%

n

%

n

%

n

%

n

This was my first
time learning about
MinION sequencing

83.3

15

5.6

1

0.0

0

5.6

1

5.6

1

I feel comfortable
preparing samples to
be sequenced on the
MinION platform
This was my first
time using
Integrative Genome
Viewer (IGV)
I feel comfortable
using IGV to
analyze genetic
variants
I have improved
upon my knowledge
in NGS technologies
due to participating
in this module

11.1

2

27.8

5

38.9

7

11.1

2

11.1

2

94.4

17

0.0

0

5.6

1

0.0

0

0.0

0

38.9

7

22.2

4

22.2

4

5.6

1

11.1

2

50.0

9

22.2

4

11.1

2

16.7

3

0.0

0
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Figure A-1. An overview of the four-week module implemented at the University of
Vermont to teach variant analysis with the MinION sequencing platform. a) Students
used primers they created to amplify DNA regions known to flank genetic variants in the
TP53, EGFR, and KRAS gene in non-small cell lung cancer (NSCLC) cells using both
single target and multiplex PCR. A portion of the PCR-product was then run on an agarose
gel for size validation while the rest of the sample was pooled and sequenced on the
MinION platform. After sequencing, students were asked to identify the starting NSCLC
cell-line by genotype analysis using Integrative Genome Viewer (IGV). B) Flowchart
summarizing the learning objections and outcomes for the four units taught.
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Figure A-2. Class amplicon pool was sequenced on the MinION and the follow-up
bioinformatic analysis performed. a) Genotyping assay was performed to amplify
regions encompassing genomic variants identified in the TP53, EGFR, and KRAS gene
(lane 3-6). A multiplex PCR reaction containing all primers of interest are shown (lane 7).
A reaction which lacked genomic DNA was included as a negative control (lane 1) while
primers amplifying a region in GAPDH was included as the positive control (lane 2). B)
Each forward and reverse primer used in the PCR reactions contained a 12-nucleotide index
at the 5’ end. c) The multiplex PCR reaction carried out by each student group were then
pooled into a single tube (class amplicon pool) and sequenced on the MinION. D) Data
output from the MinION sequencing run was analyzed using the bioinformatic pipeline
shown.
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Figure A-3. Quality of MinION sequencing reads. A) The total demultiplexed reads for
each amplicon sequenced is shown. b) Plotting the average read quality versus read lengths
(kbp). Each black dot represents a sequenced read that passed quality control cutoffs and
were then used for downstream analysis.
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Figure A-4. The Integrated Genomics Viewer (IGV) was used by students to assess
genomic variants in lung cancer cells. a) Displaying the alignment of the genomic region
amplified in the EGFR gene in HCC827 cells. A snapshot centered on the exon 19 deletion
(15 bp) is shown. The grey horizontal bar represents a mapped read, while the lack of the
grey bar indicates no reads mapped for that region. B) Displaying the alignment of the
genomic region amplified in the TP53 gene in H1975 cells. A snapshot centered on the
single nucleotide polymorphism R273H is shown. Bases that map to the reference genome
are shown in grey, while a base mismatch is colored in red.
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component analysis of samples. (C) Pathway analysis corresponding to genes in clusters
1-4 of Figure 1D.
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Appendix C-1. Serum autoantibodies and cell phenotypic analysis of Ikzf1DF4/DF4,
Ikzf1DF1/DF1, and Ikzf1wt/wt mice.(a) Heatmap showing the reactivity to antigens in the sera
of mice. Samples were clustered using hierarchical clustering. (b) Kappa, Lambda, IgG2b,
IgG1, and IgM in serum from 9-16-week-old mice by ELISA. (c) Percentage of memory
B cells (MBC), germinal center B cells (GCB), and IgG in Ikzf1DF4/DF4, Ikzf1DF1/DF1, and
Ikzf1wt/wt mice.
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Appendix C-2. Cytokine panel and kidney assessment of wt and Ikzf1DF4/DF4 mice. (a)
ELISA cytokine panel performed using the serum of Ikzf1DF4/DF4, Ikzf1wt/wt, Ikzf1DF1/DF1 ,
Ikzf1wt/DF4 from 6-week-old mice. (b) C3 deposits in glomeruli in kidneys from some 1316-week-old Ikzf1DF4/DF4 and Ikzf1wt/wt.
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Appendix C-3. Comparison of cytokine levels in spleen extracts from Ikzf1DF4/DF4 and
Ikzf1wt/wt mice.
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Appendix C-4. Gene expression comparison of Ikzf1DF4/DF4 to Ikzf1wt/wt B-cells using
RNA-sequencing. (a) Venn diagram displaying number of differentially expressed genes
(DEG) in Ikzf1DF4/DF4 or Ikzf1wt/wt B-cells unstimulated versus a-IgM. (b) Scatterplot
directly comparing a-IgM to unstimulated in Ikzf1DF4/DF4 or Ikzf1wt/wt samples. (c-e)
Pairwise comparison of Ikzf1DF4/DF4 or Ikzf1wt/wt B-cells unstimulated, a-IgM, or stimulated
with a-IgM+ CD40L. (f) Gene set enrichment analysis (GSEA) of enriched pathways in
Ikzf1DF4/DF4 or Ikzf1wt/wt. (g) Upstream regulator analysis of activated or inhibited molecules
using Ingenuity Pathway Analysis (IPA).
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Appendix C-5. Examples of cluster marker genes in Ikzf1DF4/DF4 or Ikzf1wt/wt samples
identified with single-cell RNA-seq.
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